

## **Anna-Barbara Moscicki, MD**

### **CURRICULUM VITAE**

#### **PERSONAL HISTORY:**

University of California, Los Angeles  
10833 Le Conte Ave.  
22-432 MDCC  
Los Angeles, CA 90095  
Phone: (310) 206-6345  
Email: AMoscicki@mednet.ucla.edu

#### **EDUCATION:**

1973-77	Northwestern University, Evanston, IL	BS	Medical Honors Program
1975-79	Northwestern University Medical School, Evanston, IL	MD	Medicine
1979-82	Children's Hospital of Vanderbilt, Nashville, TN	Internship/ Residency	Pediatrics
1982-84	University of California, San Francisco, San Francisco, CA	Fellowship	Adolescent Medicine
1984-85	University of California, San Francisco, San Francisco, CA	Fellowship	Sexually Transmitted Disease, Laboratory Medicine
1987-89	Stanford University, Howard Hughes Medical Institute	Fellowship	Medical Microbiology

#### **LICENSURE:**

Medical license, California G48717

#### **BOARD CERTIFICATION:**

1979	Diplomate, National Board of Medical Examiners
1984	Certified, American Board of Pediatrics
1994	Certified, American Board of Pediatrics; Sub-Board of Adolescent Medicine
2000	Recertified, American Board of Pediatrics; Sub-Board of Adolescent Medicine
2008	Recertified, American Board of Pediatrics; Sub-Board of Adolescent Medicine

#### **PROFESSIONAL EXPERIENCE:**

PRESENT POSITION

04/2015 - Present	UCLA, Los Angeles, CA	Professor of Pediatrics
04/2015 – Present	UCLA, Los Angeles, CA	Chief, Adolescent & Young Adult Medicine
02/2021- Present	UCLA, Los Angeles, CA	Chief (interim), General Pediatrics
04/2015 – Present	UCSF, San Francisco, CA	Adjunct Professor of Pediatrics

PREVIOUS POSITIONS HELD (ACADEMIC APPOINTMENTS)

07/1985-06/1990	UCSF, San Francisco, CA	Assistant Adjunct Professor
07/1990-06/1993	UCSF, San Francisco, CA	Assistant Professor in Residence
07/1993-06/1998	UCSF, San Francisco, CA	Associate Professor in Residence
07/1998-06/2011	UCSF, San Francisco, CA	Professor in Residence
07-2011-03/2015	UCSF, San Francisco, CA	Professor, Tenure

ANCILLARY POSITIONS HELD CONCURRENTLY

1986-2015	UCSF, San Francisco, CA	Director, Teen Colposcopy Clinic, Div. of Adolescent Medicine
1990-2010	UCSF, San Francisco, CA	Director of Medical Student Education in Adolescent Medicine
1994-2012	UCSF, San Francisco, CA	Director of Clinics, Adolescent Medicine
1999-2015	UCSF, San Francisco, CA	Associate Director, Adolescent Medicine
2000-2004	UCSF, San Francisco, CA	Senior Director, Glaser Foundation, Pediatric Clinical Research Network
2002-2006	UCSF, San Francisco, CA	Associate Director, Pediatric Clinical Research Center
2010-2015	UCSF, San Francisco, CA	Director, Junior Investigator Review Committee
2013-2015	UCSF, San Francisco, CA	Vice-Chair of Clinical and Translational Research, Department of Pediatrics
2013 - 2015	UCSF, San Francisco, CA	BRAID (Biomedical Research Acceleration, Integration and Development) Child Health, UCSF representative
2013-2015	UCSF, San Francisco, CA	Medical Director, CTSI Pediatric Clinical Research Center
2015 - Present	UCSF, San Francisco, CA	Adjunct Professor of Pediatrics
2015 – Present	UCLA, Los Angeles, CA	Chair, Clinical Trial Oversight Committee, Department of Pediatrics
2016- Present	UCLA, Los Angeles, CA	Associate Vice Chair, Clinical Research Department of Pediatrics
2016-Present	UCLA, Los Angeles, CA	Executive Committee, Children’s Discovery and Innovation Institute, Department of Pediatrics

## PROFESSIONAL ACTIVITIES:

### CLINICAL

Attending Adolescents Medicine Service

### CLINICAL EXPERIENCE

- 1982 Staff Physician: Planned Parenthood, Teen Clinics, San Francisco  
1983-84 Staff Physician: Youth Guidance Center, Juvenile Hall Medical Clinic, Department of Forensic Medicine, San Francisco  
1983-2015 Attending Physician: General Adolescent Clinic Adolescent Gynecology Clinic, Sports Medicine Clinic, University of California, San Francisco  
1984-85 Staff Physician: San Francisco City VD Clinic  
1986 Basic Colposcopy Course, Presented by the University of Toronto, Canada; San Francisco, CA  
1986 Colposcopy Training, supervised by M. Roy, M.D. at Universite Laval, Quebec, Canada  
1987 Staff Physician, Acting Medical Director, Larkin Street Medical Clinic for Runaway Youth  
2015- Staff Physician, Mattel's Children Hospital, UCLA; Los Angeles, CA  
2016- Staff Physician, Northeast Valley Clinic, Los Angeles, CA

### *TEACHING AND MENTORING*

#### TEACHING: FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS:

<b>Qrt.</b>	<b>Acad.Yr.</b>	<b>Course No. &amp; Title</b>	<b>Nature of Contribution</b>	<b>Units</b>	<b>Class Size</b>
W	2001-02	Fresno Medical Ctr	1 day course	4 hrs	30
W	2003	<b>Fresno Medical Ctr</b>	1 day course	4 hrs	30
W	2002	Adolescent Medicine Lecture Series	Lecture	12 hrs	4
W	2003	Adolescent Medicine Lecture Series	Lecture	12 hrs	4
W	2004	Adolescent Medicine Lecture Series	Lecture	12 hrs	4
W	2003	Life Cycle Course (UCSF)	Small Group Leader	12 hrs	20
W	2004	Life Cycle Course (UCSF)	Small Group Leader	8 hrs	20
W	2005	Life Cycle Course (UCSF)	Small Group Leader	8 hrs	20
W	2006	Life Cycle Course (UCSF)	Small Group Leader	8 hrs	20
W	2007	Life Cycle Course (UCSF)	Small Group Leader	8 hrs	20
W	2009	Life Cycle Course (UCSF)	Co-Leader	8 hrs	20

W	2010	Life Cycle Course (UCSF)	Co-Leader	8 hrs	20
W	2011	Life Cycle Course (UCSF)	Co-Leader	8 hrs	20
W	2012	Life Cycle Course (UCSF)	Co-Leader	8 hrs	20
W	2013	Life Cycle Course (UCSF)	Co-Leader	8 hrs	20

POST GRADUATE COURSES SPONSORED BY UCSF:

Class					
<u>Qrt</u>	<u>Acad</u> <u>Yr.</u>	<u>Course No. &amp; Title</u>	<u>Nature of Contribution</u>	<u>Units</u>	<u>Size</u>
W	1987-88	Advances in Pediatrics	Lecture and Panel Discussions	1 hr	300
W Su	1993-94 2013	Continuing Education University of California, San Francisco, BIRCWH Women's Health Seminar, "Heterosexual transmission in women and anal HPV infections"	Didactic lecture, July 2		

POST GRADUATE COURSES SPONSORED BY UCLA:

<u>Acad</u> <u>Yr.</u>	<u>Course No. &amp; Title</u>	<u>Nature of Contribution</u>	<u>Units</u>	<u>Size</u>
2015-Pr	PE350.04 Adolescent Medicine	Lecturer	1 hr	7*

\*required for residents and 4<sup>th</sup> year medical students with elective rotations

POSTDOCTORAL FELLOWS SUPERVISED:

<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
1985-87	Regina Mills, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Dir., Adol. Med., Long Island College Hospital
1985-88	Sheryl Ryan, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Prof. Peds., University of Rochester
1986-87	Thomas Kunstman, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Staff Phys., University of Colorado

<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
1986-88	Todd Jacobs, M.D., (deceased)	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Dir., Teen and Young Adult Svcs., Adol. Med., Kaiser Walnut Creek, CA
1987-89	Seth Ammerman, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Clin. Prof. Peds., Stanford University, CA
1987-89	Karen Kamachi, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Pediatrician, private practice, Salinas, CA
1988-90	Janet Chaikind, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Supervising Physician, San Mateo County General Hospital
1988-90	Norman Schlossberger, M.D., (deceased)	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	former faculty, Adol. Med., Stanford University, CA
1989-90	Davida Talcove, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Med. Director, San Mateo County Clinic
1990-92	Elissa Gittes, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Pediatrician, Pedimedica, PA
1990-92	Merula Franzgrote, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Dir., Teen Health Ctr., Adol. Med., Kaiser Hayward, CA
1990-92	Vivien Igra, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Dir., Teen and Young Adult Svcs., Adol. Med., Kaiser Walnut Creek, CA
1991-93	Jonathan Ellen, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Asst. Prof. Peds., Adol. Med., Johns Hopkins

<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
1991-93	Cynthia Kapphahn, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Clin. Prof., Adol. Med., Stanford University, CA
1992-94	Carol Ford, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Associate Professor of Pediatrics, University of North Carolina
1993-96	David Bell, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Pediatrician, St. Luke's Hospital, NY
1994-97	Scot Lappa, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Asst. Clin. Prof. Peds., University of Alberta, Canada
1994-97	Leslie Walker, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Asst. Prof. of Pediatrics, Georgetown University
1995-97	Margo Lane, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Prof. of Pediatrics, University of Manitoba
1995-00	Mark Scott, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Asst. Research Immunologist, UCSF
1996-99	Tonya Chaffee, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Clinical Professor, UCSF
1997-00	CoCo Auerswald, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Adjunct Professor, UCSF
1997-00	Mary Ott, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Prof., Indiana University
1997-00	Arik Marcell, M.D.	Postdoctorate Fellow, Adolescent	Clinical Mentor	Asst. Prof., University of Maryland

<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
		Medicine		
1998-01	John Sieverding, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Research Epidemiologist, UCSF
1999-02	Diane Straub, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Director of Adolescent Medicine, U of South Florida
1999-02	Mark Rubinstein, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Asst. Adjunct Professor, UCSF
1999-02	Sophia Yen, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Clinical Instructor, Stanford; MPH Program, UC Berkeley
2002-03	David Breland, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	
2002-03	Donna Carey (White), M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Medical Director, Pediatric Hospitalist Program & Neonatal ICU, Emanuel Medical Center, Turlock, CA
2002-05	Martha Perry, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Pediatrician, Westwood-Mansfield Pediatrics
2003-06	Jennifer Carlson, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Pediatric Clinical Instructor, Stanford School of Medicine
2003-06	Loris Hwang, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Associate Professor, UCLA
2003-06	Lea Widdice, M.D.	Postdoctorate Fellow,	Clinical Mentor,	Asst. Prof. of Pediatrics,

<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
		Adolescent Medicine	Research Mentor	Cincinnati Children's Hospital Medical Center
2004-07	Sara Buckelew, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst. Clin. Professor, UCSF
2004-07	Catherine Miller, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Clinical Instructor, Adolescent Medicine, Stanford University,
2006-07	Loris Hwang, M.D. (T32)	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor, Research Mentor	Associate Professor, UCLA
2006-07	Ibrahim Daud (Graduate Student, Kenya)	Pre-doctorate Fellow	Research Mentor	Kenya Medical Research Institute, Nairobi, Kenya
2006-08	David Breland, M.D., M.P.H.	Postdoctorate Fellow, Adolescent Medicine	Research Mentor	Assistant Professor, University of Washington, Seattle
2006-08	Jennifer Edman, M.D., M.P.H.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Student Health Service, Oregon State University
2006-	Carolyn Jasik, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Asst Clinical Prof, UCSF
2007- 09	Melissa Slivka, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Director, Young Adult Medicine, Kaiser Permanente, Vallejo, CA
2007-10	Dzung Vo, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Ass. Prof., British Columbia, Children's Hospital



<b>Dates</b>	<b>Name</b>	<b>Program or School</b>	<b>Role</b>	<b>Current Position</b>
2008-11	Melissa Pujazon, M.D., M.P.H.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Director, Adolescent Medicine, Kaiser, Downey
2008-11	Jiraporn Prasertwit, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Director, Adolescent Medicine, Mahidol University, Bangkok, Thailand
2010-13	Lauren Hartman, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Director, Adolescent Medicine, Kaiser, Oakland
2010-13	Josephine Lau, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Assistant Professor of Pediatrics, UCSF
2010-13	Hilary Wolf, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Assistant Professor of Pediatrics, Georgetown University
2012-14	Stephanie Adrianse, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Current Fellow
2012-15	Marissa Raymond-Flesh, M.D.	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	Current Fellow
2012-13	Marie-Claude Couture, PhD, MS	Postdoctoral Scholar	Research Mentor	Pd Dir, UCSF Dept of Epi and Biostatistics, Institute of Global Health
2012-15	Kelly Benedict, MD	Postdoctoral Scholar	Research Mentor	Clinical Fellow, UCSF Department of Pediatrics (Nephrology)
2012-14	Raphael Omusebe Ondondo, PhD	Postdoctoral Scholar	Research Mentor	Laboratory Research

Dates	Name	Program or School	Role	Current Position
				Scientist and Laboratory Director, Kenya Medical Research Institute
2013	Yasmin Leela Jayasinghe, PhD	Postdoctoral Scholar, University of Melbourne, School of Graduate Research	Thesis Examiner	University of Melbourne, Instructor
2013-15	Stanley Vance, MD	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	UCSF, Assistant Professor
2014-15	Veronica Mesheriakova, MD	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	UCSF
2014-15	Megen Vo, MD	Postdoctorate Fellow, Adolescent Medicine	Clinical Mentor	UCSF Fellow
2017-18	Narissa Nonzee	Predocctoral UCLA School of Public Health	Research Mentor	Post-doctorate UCLA
2017-18	Gordana Halec, PhD	Postdoctoral Fellow	Research Mentor	Research Associate
2019-20	Sarah Martin, PhD	Postdoctoral Fellow	Research Mentor	
2020-	Marciana Laster	Assistant Professor, UCLA	Faculty Mentor	

**MEDICAL STUDENTS SUPERVISED/MENTORED:**

2003-04 Doris Duke Medical Student Jay Leiberman  
1997-98 Year-long Research Project: Vanessa Grubbs, Duke Medical School, U of Tennessee, Memphis  
2011-12 UCSF Medical Student Justin Miyamoto, Thesis Committee  
2011-12 Imperial College London (UK) Medical Student Tania Wan, Research Medical Elective: Stress and HPV Persistence  
2016-2017 Mariel Bailey, Research Elective, UCLA Medical School, “Text Messaging to Increase HPV Vaccination Rates in Children”.

- 2016-2017 Betelhem Kifle, Research Elective, UCLA Medical School, “Helping Teenagers with DM Transition to Adult Care”.
- 2018 Gillian Foley, Research Elective, UCLA Medical School, “Colposcopy impressions after HPV vaccination”.
- 2016-2020 Betelhem Kifle, Research Elective, UCLA Medical School, “Helping Teenagers with DM Transition to Adult Care” and "Cytokine response to HPV in HPV unvaccinated women and previously HPV vaccinated"
- 2018-2021 Gillian Foley, Research Elective, UCLA Medical School, “Colposcopy impressions after HPV vaccination”.
- 2019-2020 Kelly Darmawan, Research Elective, UCLA Medical School, "Factors influencing provider implementation of cervical cancer screening guidelines: A qualitative study"

**High School Students Supervisions/Mentor**

- 2016-2017 Mirand Huang, UCLA High School Student, High School Project, Salnary Protein Express in Women Using Cigarettes, Alcohol and Marijuana.

INFORMAL TEACHING:

2015-pr.	General Attending Inpatient Ward Rounds for Adolescent Medicine	Discuss inpatient cases	1 hr/day As needed	2-4
2015-pr.	Consultant in Adolescent Clinic	Discuss cases with Residents/ Medical Student	5 hr/wk	4-6
2015-pr.	Adolescent Rotation Residents/Medical Student	Hour lecture	1 hr/mo	3-7
2015-pr	Fellow College, Department of Pediatrics	Career grant discussion with fellow	4 hours/yr	4-6
2015-pr	Noon conference, Department of Pediatrics	Lecture	1 hr/yr	20

TEACHING AIDS PREPARED:

- 1984-85 Guidelines for the Diagnosis, “Treatment and Interviewing of Sexually Transmitted Disease,” Department of Public Health, SF
- 1984-91 Teaching handouts for students and patients
- 1986-87 Syllabus to Housestaff: Adolescent gynecology
- 1986-87 Participant in the making of the videotape: "Adolescent Medicine: The Second Decade of Life", McNeil Consumer Products, prepared in our Division and distributed to all

Departments of Pediatrics and Family Medicine in the U.S.A.  
 1992 HPV information handout  
 2000 Adolescent Medicine Clinic Forms

**SUMMARY OF TEACHING HOURS:**

2011-12	400 total hours of teaching Formal class or course teaching hours: 4 hours <b>Informal teaching hours: 300 hours</b> Mentoring hours 100
2012-13	400 total hours of teaching Formal class or course teaching hours: 4 hours <b>Informal teaching hours: 300 hours</b> Mentoring hours 100
2013-14	400 total hours of teaching Formal class or course teaching hours: 4 hours <b>Informal teaching hours: 300 hours</b> Mentoring hours 100
2014-15	254 total hours of teaching Formal class or course teaching hours: 4 hours <b>Informal teaching hours: 200 hours</b> Mentoring hours: 50
2015-16	450 total hours of teaching <b>Informal teaching hours: 300 hours</b> Mentoring hours: 150
2016-17	400 total hours of teaching <b>Informal teaching hours: 300 hours</b> Mentoring hours: 100
2017-18	400 total hours of teaching <b>Informal teaching hours: 300 hours</b> Mentoring hours: 100
2018-19	400 total hours of teaching <b>Informal teaching hours: 300 hours</b> Mentoring hours: 100
2019-20	400 total hours of teaching <b>Informal teaching hours: 300 hours</b> Mentoring hours: 100

VISITING PROFESSORSHIPS

1993 MacFarlane Burnett Research Center, Fairfield, Victoria Australia  
 2003 Family Planning Council, Philadelphia, PA  
 2014 University of California Los Angeles, Sabbatical  
 2015 University of California Los Angeles, Visiting Professor

## SUMMARY OF TEACHING:

Besides the teaching activities described under Clinical activities, which include supervision of 3-4 residents and 3-4 medical students, I am also the primary mentor for Loris Hwang, a junior faculty member of the Department of Pediatrics at UCLA. I now teach residents and medical students at UCLA which rotate through Adolescent and Young Adult Medicine rotation. I had been involved in several years in the Life Cycle course for medical students as a small group leader and in 2009 took on the role as co-leader with Dr. Mark Rubenstein. I am responsible for one of the core lectures for UCLA residents and medical students rotating each month and share responsibility with other Adolescent Medicine faculty for the patient management in Santa Monica Hospital. I have also mentored both international and national students. Currently, I mentor a post-doctoral student in my laboratory, 2 UCLA medical students, a pre-doctoral in the School of Public Health and post-doctoral psychologist in Pediatrics. I also have taught at numerous clinical meetings as invited speaker both nationally and internationally including countries in Africa, South America, Asia and Europe (see Invited Lectures below).

## UNIVERSITY AND PUBLIC SERVICE:

### MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

1982- Society for Adolescent Medicine  
1984-94 American Medical Association  
1983- American Academy of Pediatrics, Fellow  
1987- American Venereal Disease Association  
1990- Western Society for Pediatric Research  
1989 International Society for Adolescent Medicine  
1991- Society for Pediatric Research  
2007- International Papillomavirus Society  
2007- American Society for Colposcopy and Cervical Pathology  
2010- American Pediatric Society  
2013- International Anal Neoplasia Society

### SERVICE TO PROFESSIONAL ORGANIZATIONS

#### *Society for Adolescent Medicine*

1991-2006 Membership Committee  
1991-2002 Mentorship program, Chair  
1991-2006 Abstract Selection Committee  
1998 AIDS in Adolescents: Exploring the Challenge. National Invitational Conference, Society for Adolescent Medicine/Maternal and Child Health, (Prevention and Education)  
2004-2007 Vaccine Committee  
2016- Program Committee  
2016- Awards Committee

*Society for Adolescent Medicine, Northern California Chapter*

1997-2000    President

*American Academy of Pediatrics, Northern California Chapter*

1990-2000    Youth Committee

*National Board of Medical Examiners*

1994-1997    United States Medical Licensing Examination Committee, Pediatrics, Step II  
Subgroup

*American Board of Pediatrics*

1998-2004    Member, Sub-Board of Adolescent Medicine

*Society for Pediatric Research*

1997- 2001    Representative to the joint American Academy of Pediatrics' program, "Faculty  
Development for General Pediatrics Generalists Faculty Training in Community-  
Based Ambulatory Settings."

2015-16      Mentor Program

*American Medical Association*

1997          Consensus Meeting on Diagnosis, Management and Education of External Genital  
Warts

*American Society for Colposcopy and Cervical Pathology*

2002-6        Practice Committee

2002-        Liaison to the American College of Gynecology, Committee on Adolescent  
Health Care

2002-6        Patient Education Committee

2005-6        Chair, Youth Committee

2006-7        Chair, Young Women Working Group

2008-        Board Member

2009-        Chair, Special Populations Committee

2009-        Chair, Practice Improvement in Cervical Screening and Management (PICSM)  
Committee's Symposium on Cervical Cancer Screening and Management of  
Cervical Abnormalities in Adolescents and Young Women. Sponsored by the  
ASCCP, June, 2009, Washington DC

2010-        Working Group Member, Practice Improvement in Cervical Screening and  
Management (PICSM) Committee's Symposium on HPV Testing: Impact of HPV  
Vaccination Working Group. Sponsored by the ASCCP, Washington DC

2012        Course Director, 2012 ASCCP Biennial Scientific Meeting: Special Populations  
Workshop. San Francisco, CA, March 14.

2013        Consultant to the 21-24 year old age group: 2012 updated consensus guidelines  
for the management of abnormal cervical cancer screening tests and cancer  
precursors.

2013        Assistant Secretary

2014 Secretary  
 2015 Treasurer  
 2015-16 Chair, Consensus Committee Anal Cancer Screening in Women  
 2016 President-elect  
 2016- Research Committee  
 2016-17 Member: Colposcopy Standards Working Group  
 2017-18 President,  
 2017-19 Chair, Cervical Cancer Screening in non-HIV Immunocompromised Women working group  
 2018-19 Chair, Anal Cancer Screening in Women working group

*American Cancer Society*

2005 Chair, “When To Start Screening” New recommendations.  
 2011 Working group, “Screening HPV vaccinated women”  
 2015-19 HPV Vaccine Roundtable; working group member

*International Papillomavirus Society*

2018-pr Board Member

SERVICE TO PROFESSIONAL PUBLICATIONS

1986- Journal of Adolescent Health Care, Anonymous Reviewer  
 1987- Journal of Pediatrics, Anonymous Reviewer  
 1990- Journal of Clinical Investigation, Anonymous Reviewer  
 1990- Journal of American Medical Association, Anonymous Reviewer  
 1990- Sexually Transmitted Diseases, Anonymous Reviewer  
 1991- Journal of Infectious Diseases, Anonymous Reviewer  
 1992- Obstetrics and Gynecology, Anonymous Reviewer  
 1994- Journal of Clinical Microbiology, Anonymous Reviewer  
 1997- Pediatrics, Anonymous Reviewer  
 1997- Urology, Anonymous Reviewer  
 2009- International Journal of Cancer, Anonymous Reviewer

EDITORIAL BOARDS:

1997 - 2006 Clinical and Diagnostic Laboratory Immunology, Editorial Board Member  
 2001- 2017 Sexually Transmitted Diseases, Editorial Board Member

SCIENTIFIC AND PROFESSIONAL MEETINGS AND WORKSHOPS ATTENDED:

*International:*

International Human Papillomavirus Workshop, 1987 to present, chair, papers, and invited lectures  
 International Society for Sexually Transmitted Diseases, 1991, 1997 (papers), 1999  
 AIDS International Meetings 1998, 2000, 2002  
 Eurogin: Multidisciplinary Congress on Cervical Cancers, 2000, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2018, 2019  
 International Associations of Cancer Registries, Beijing, China, 2004

University of Nairobi, STD/AIDS Collaborative Group: Annual Review Meeting, Nairobi, Kenya, 2005

International Microbicide Meeting, 2008, 2010

7th World Workshop on the Mouth and AIDS: Lessons Learned and Emerging Challenges in Global Oral Health, Hyderabad, India, Chair of Workshop on virus associated oral cancers in HIV infected persons, November 6-9, 2014.

Obstetrics and Gynecology Resident Colposcopy, Cryotherapy and LEEP, M'ekelle University, M'ekelle, Ethiopia, October 8-9, 2014. Lectures: "HPV and HIV," "HPV Vaccines," "HPV Testing: Its Use In Developed And Developing Countries," "An Overview of Colposcopy: The Normal Transformation (T) Zone."

*National:*

Society for Adolescent Medicine, 1983 (workshop), 1984 (workshop), 1985 (paper), 1986 (paper), 1987 (paper), 1989 (paper), 1990 (paper), 1992 (workshop), 1995 (workshop), 1996 (workshop), 1997 (workshop), 1999 (workshop, papers), 2000 (workshop, papers), 2001 (workshop, papers), 2002 (invited lecture), 2003 (invited lecture), 2004 (invited lecture), 2005 (symposium), 2006 (invited lecture), 2007 (invited lecture), 2008 (invited lecture), 2010 (invited lecture), 2015, 2018

American Academy of Pediatrics, 1983 (workshop), 1984 (workshop), 1992 (workshop), 1995 (workshop)

Society for Pediatric Research, 1983 (paper), 1985 (paper), 1988-91 (papers)

American College of Physicians, 1989, 1998 (invited lecture)

American College of Surgeons 2014 (invited lecture)

Pediatric Academic Societies, 2002 (invited lecture), 2003, 2004, 2006

American Society for Colposcopy and Cervical Pathology, 2002 to present (invited lectures)

*Regional:*

Society for Adolescent Medicine, Northern California Chapter, 1982 to present (invited lectures, discussant)

Western Society for Pediatric Research 1991, 2006 (invited lecture), 1993 (section chair)

SERVICE TO GOVERNMENT:

1992 NIH: Grant Review, Special Reviewer

1994 NIH: STDs and Adolescents: Future Research Agendas. Invited Participant, Annapolis, MD

1994-2001 NIH: Chair, Basic Science Group: Adolescent Medicine HIV/AIDS Research Network

1997 NIH: Participant in National Institute on Drug Abuse Development of a POSIT - HIV/STD Mini-questionnaire workshop

1998 PACTG (Pediatric AIDS Clinical Trials group) - consultant

1998-1999 Office of AIDS Research - Working group to review the NIH Perinatal, Pediatric and Adolescent HIV Research Priorities.

1999- pr. NIH: Member of AIDS and Related Research Study Section: Vaccines

2001 Society for Adolescent Medicine/CDC/APA Immunization Small Grants Program (Committee Member)

2002 CDC: Special Emphasis Panel: Integrated Multi-level Interventions to Improve



- Adolescent Health through the Prevention of Sexually Transmitted Diseases
- 2002- pr. PACTG Member, consultant
- 2002 National Cancer Institute, member, Working Group, Journal of National Cancer Institute, Monograph on HPV epidemiology
- 2005 NIH: SPORE in Ovarian and Gynecologic Cancers, reviewer.
- 2006- NIH: Cancer Etiology Cluster Group, adhoc reviewer
- 2006 NIAID: Development of Standardized Microbicide Toxicity Tables for Clinical Trials, Topical Microbicide Team, Division of AIDS and STI Branch, Division of Microbiology and Infectious Diseases
- 2006 NCI: Annual Meeting of the NCI Cohort Consortium
- 2006 Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), Topical Microbicide Team; Development of Standardized Microbicide Toxicity for Clinical Trials (workshop); September.
- 2007 American Society for Colposcopy and Cervical Pathology (ASCCP): 2007 ASCCP Guidelines
- 2007 Centers for Disease Control and Prevention (CDC): Expert Panel Member, National Gynecologic Cancer Awareness Campaign
- 2007 NIH ad hoc reviewer, Cancer Genetics and Epidemiology
- 2008 NIH ad hoc reviewer, Cancer Genetics and Epidemiology
- 2008 NIH ad hoc reviewer, Small Grants for Behavioral Research in Cancer Control
- 2008 NIH Pediatrics HIV Prevention opportunistic infection guidelines; 2008 contributor to section on HPV
- 2008 NIH members study conflict section reviewer
- 2008 CDC Special Emphasis Panel reviewer
- 2008 Member, Conflict Special Emphasis Panel; NIH review, September 23<sup>rd</sup>; Neurological, Aging and Musculoskeletal Epidemiology (NAME) Study Section. Health of the Population (HOP) Integrated Review Group.
- 2009 NIAID/NIH/DHHS: STI CRC review committee
- 2009 NIH IRAP study section reviewer
- 2009 NIH Z RGIIMM – E: Center for Scientific Review Special Emphasis Panel
- 2009 NIH Special Emphasis Panel, ZAI1-MMT M (M1): Sexually Transmitted Infections Cooperative Research Centers
- 2009 NIAIDS IRAP: Challenge grant review committee
- 2009 NIH Center for Scientific Review, special emphasis panel, October 1-2
- 2010 NIH IRAP study section reviewer
- 2011- pr. NIH Loan Repayment Program, Reviewer
- 2012- pr. Center for Disease Control: Diagnosis and Treatment of Opportunistic Infection in HIV infected children: author HPV infection section
- 2012- pr. Center for Disease Control: Diagnosis and Treatment of Opportunistic Infections in HIV infected adolescents and adults (MMWR): author HPV infection section
- 2013 NIH, Tumor Immunology R03/R21: Therapeutics, Review committee member, June 26-27
- 2013 National Cancer Institute, Infection and Immunology Branch: Site visit committee member, PI review, July 9-10
- 2013 NIAID, Immune Mechanisms of Virus Control (U19), reviewer
- 2014 NIH IRAP study section reviewer

- 2014 NIH-CDC-HIVMA/IDSA Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: committee member, HPV group
- 2014 NIAIDS, AIDS Research Review Committee, K01 application review, July 15th.
- 2015 National Cancer Institute: Review of the NCI Infections and Immunoepidemiology Branch, March 25-27
- 2016 NIH/NAIDS, Human Immunology Project Consortium, ad hoc reviewer, July 18-20
- 2017 NIH International Research in Infectious Disease including AIDS, ad hoc reviewer, Dec. 5<sup>th</sup>
- 2018-pr National Cancer Institute and ASCCP Risk-Based Management Consensus Guidelines: Co-Chair, Risk Modification Working Group
- 2019 National Cancer Institute Infections and Immunoepidemiology Branch Peer Review, Reviewer
- 2019 Federal Drug Administration, Microbiology Devices Panel Meeting March 8, 2019, Expert Panel Member
- 2020 NIH Special Emphasis Panel: HIV/AIDS associated disease; December 19, 2020

UNIVERSITY AND PUBLIC SERVICE

*University of California, Los Angeles, Academic Senate service*

2020- Legislative Assembly member for Department of Pediatric

*University of California, Los Angeles, Department of Pediatrics:*

- 2015- UCLA Children's Discovery and Innovation Institute (CDI) Steering Committee, member
- 2015- Pediatrics Clinical Trials Oversight Committee, Chair
- 2015- Janet and Ray Scherr Fellowship Loan Repayment Program Review Committee, Member
- 2015- UCLA CDI Junior Faculty Review, Member
- 2015- CDI Seed Grant Review Committee, Member
- 2016- Associate Chair, Clinical Research, Department of Pediatrics
- 2016 CDI Executive Committee member
- 2016-17 Member search committee, Chair of Endocrinology, Department of Pediatrics
- 2016- CTSI, Special Population Member
- 2016- CTSI, Junior Faculty Grant, Reviewer
- 2018 Sherrman M. Mellinkoff/Leonard Tow Award Committee, Member
- 2018- Chair, Search Committee for General Pediatrics Chair

*University of California, San Francisco, School of Medicine:*

- 1990- Committee Service, Science and Health Partnership Program, member
- 1994 Ad-Hoc Review Committee, CAP
- 1995-97 Ad-Hoc Review Committee CAP, Chair
- 2002 Ad-Hoc Review Committee, CAP, Chair
- 2003 Ad-Hoc Review Committee, CAP, Chair
- 2006-08 UCSF CTSI Clinical Research Center, Community Engagement Program Member

- 2008 COR (Clinical Outcomes Research), subcommittee member and Chair of review committee
- 2008 Academic Affairs, Search Committee, Chair
- 2009-2009- COR (Clinical Outcomes Research) subcommittee member, Dept of Internal Medicine
- 2010 CFAR, HIV and malignancy grant reviewer
- 2010 Department of Internal Medicine, search committee member
- 2011-14 CFAR, HIV and Malignancies Review Committee
- 2012- UCSF Building Interdisciplinary Research Careers in Women's Health (BIRCWH), Advisory Board
- 2012 UCSF CFAR Clinical HIV/AIDS Study Section
- 2012 UCSF CTSI RAP Cancer Study Section
- 2013-14 UCSF Cancer Resource Allocation Program (RAP) Review Committee

*University of California, San Francisco, Department of Pediatrics:*

- 1990-91 Ad Hoc Search Committee, Division of Adolescent Medicine Faculty
- 1990- Clinical Services Committee, Division of Adolescent Medicine
- 1990- Research Committee, Division of Adolescent Medicine
- 1994 Committee for Clinic Re-organization
- 1997 Search Committee, Jr. Faculty, Division of Adolescent Medicine
- 2000 Search Committee, Jr. Faculty, Division of Adolescent Medicine
- 2002-06 Clinical Translational Research Group, Membership Chair
- 2003-06 Pediatric Clinical Research Center Advisory Committee
- 2003 Leadership Group
- 2009- Department of Pediatrics, Chair, junior investigator grant review board
- 2009-12 Department of Pediatrics T32 committee review member
- 2013 Vice-Chair of Clinical and Translational Research, Department of Pediatrics
- 2013 BRAID-Children's Health UCSF representative
- 2013 UCSF Helen Diller Family Comprehensive Cancer Center, Spring RAP Reviewer

PUBLIC SERVICE

- 1983 Health Education: San Francisco Unified School District
- 1984-85 San Francisco Department of Public Health: Committee Member for Sexually Transmitted Disease Protocols
- 1985 San Francisco Department of Public Health Youth Service Coordinating Committee
- 1985 Sports Physicals: Lincoln High School
- 1985 Sports Physicals: MacAteer High School
- 1985-90 Consultant to Department of Public Health VD Clinic, San Francisco: Strategies for Adolescent Health Education
- 1985 Marin County High School: Discussant Adolescent Suicide and Development
- 1986-89 Sex Education: San Francisco Public High Schools
- 1986 Sports Physicals: Mission High School
- 1986 Sexually Transmitted Disease Education Classes Balboa High School
- 1986-89 San Francisco Department of Public Health: AIDS Adolescent Task Force.
- 1986-88 San Francisco Department of Public Health. Mission High School Health Clinic Advisory Group.

- 1987-90 Advisory Board, Girls Only Magazine for Young Teens, Whittle Communications
- 1987-89 San Francisco Department of Public Health. Adolescence Health Advisory Board
- 1987-88 STD Update for Department of Public Health: In Services
- 1987-88 Larkin Street Youth Medical Center for the Homeless, Department of Public Health, San Francisco, California, Staff Physician
- 1987-89 Department of Public Health, Committee on Adolescent Health Care
- 1988- Interagency Outreach Council: HPV consultant, Department of Public Health, San Francisco
- 1988-89 Consultant, Roman Catholic Archdiocese: AIDS Education in Adolescents
- 1989 Community Health Talk, University of California, San Francisco
- 1990-94 San Francisco Sexually Transmitted Disease Prevention/Training Center Staff. Intensive STD training course. Faculty. HPV Infections: Diagnosis and Treatment Course, quarterly
- 1990 Oakland Department of Public Health. In Service Training of Staff: STDs and Adolescents
- 1990,92 Santa Rosa Community Hospital: Grand Rounds
- 1992-98 Cole Street Clinic, Department of Public Health, San Francisco, Supervise Colposcopy Clinic, Permanente, lecturer
- 2000 San Francisco State University, Doctor Bermudez Lecturer, "Issues in College Health"
- 2004 American Academy of Family Physicians. Faculty: "Infant Child, and Adolescent Medicine" continuing medical education course, November 16-21
- 2007 Marin General Hospital: Grand Rounds, "HPV Vaccines," May 18.
- 2007 California Pacific Medical Center: Grand Rounds, "HPV Vaccines," May 31.
- 2008 *Permanente Medicine Women's Health: Cervical Cancer Screening* video conference, Northern California Kaiser Permanente, October 23.
- 2012 "Why We Need to Vaccinate Boys and Men for HPV." UCSF Dermatology Grand Rounds lecture, October 17.
- 2013 "The Long Road to Understanding the Natural History of HPV," Educational Activity, San Francisco State University, San Francisco, CA, December 4.
- 2017- Department of Public Health, CLAC, Adolescent Workgroup
- 2017- Los Angeles HPV Vaccine Coalition

#### NATIONAL/INTERNATIONAL CONSULTANT SERVICE:

- 1987 Consultant on AIDS and STDs, Swedish National Board of Health and Welfare.
- 1992 HPV Seminar on Vaccines, Chiron, Emeryville, CA, November
- 1997 Consensus Panel on Management and Treatment Guidelines for External Genital Warts, Sponsored by the American Medical Association.
- 1997 Aldara National Consultants Meeting, Phoenix, AZ, March
- 1998 Tobacco Etiology Research Network, Invited Conference Participant, Robert Wood Johnson Foundation, Pittsburgh, PA.
- 1999 Participant in the Working Group to review the NIH Perinatal, Pediatric and Adolescent HIV Research Priorities, Office of AIDS Research, NIAID, NICHD, June 10,11.
- 1999 Prevention of Genital HPV Infection and Sequelae: Report of an External

- Consultants' Meeting; Division of STD Prevention, Centers for Disease Control and Prevention, December
- 2000 Consultant for the HPV section of the STD Treatment Guidelines
- 2000-1 Advisory Group Member for the *Faculty Development for General Pediatrics Generalist Faculty Teaching in Community Based Ambulatory Setting* (Contract No. 240-97-0043), funded by the Health Resources and Services Administration (HRSA) and administered by the Ambulatory Pediatric Association (APA)
- 2001-3 American Cancer Society, Chair of working group to establish guidelines for “When To Start Screening.”
- 2002 American Society for Colposcopy and Cervical Pathology, Delegate Consensus Conference on the Management of Cytological Abnormalities and Cervical Cancer Precursors
- 2003 HSV Vaccines in Adolescents, GlaxoSmithKline, Paris, France
- 2003 Consultant to GlaxoSmithKline, Herpes Simplex virus vaccines: Phase III Trial
- 2003 Consultant, Global Campaign, Ethics and Issues in Clinical Trials of Vaginal Microbicides
- 2003-4 Consultant to Merck, HPV Vaccine development
- 2004-8 Data and Safety Monitoring, Board Member, Glaxo SmithKline, HSV vaccine trial
- 2004-7 Merck HPV Vaccine: Adolescent Advisory Board
- 2005-6 GlaxoSmithKline: HPV Vaccine Advisory Board
- 2005 HPV and Cervical Cancer Expert Meeting, London, England
- 2005 Technical Workshop on Cellular-Mediated Immunity to HPV: Prospects for Vaccine Development, WHO Geneva, Switzerland
- 2005 Co-Chair, 22<sup>nd</sup> International Papillomavirus Conference and Clinical Workshop, Vancouver, Canada, April 30-May 6
- 2005 Think Tank Meeting of Cervical Cancer Vaccination Board, Barcelona, Spain
- 2005-6 Global Cervical Cancer Prevention Board, Vancouver
- 2006 Vaccine Monograph: HPV vaccines and Screening in the Prevention of Cervical Cancer: Writing Member, London England
- 2008 Society of Gynecologic Oncologists: Future strategies of cervical cancer prevention: what do we need to do now to prepare, Chicago, IL, September (invited participant)
- 2009 Consultant, BT Pharma SA, PC10VAC01: Tolerance and Immunogenicity of Procervix, A Candidate Vaccine Composed of 2 Recombinant Adenyl Cyclases for Treatment of Hpv 16 or/and 18 Infected Women to Prevent Cervical Cancer
- 2010-pr Merck Global Advisory Board on HPV vaccines
- 2012 General Peer Review Meeting, HPV and Cancer Prevention Monograph Program, Sitges, Spain March 21-24.
- 2013-14 Consultant to the National Institute of Public Health, Mexico, Biosafety Commission, Working Group Meeting: Tlaxcala Cervical Screening Study, March 7.
- 2013-15 Molecular Triage in Cervical Cancer Prevention: the Puebla City Study, Chair, Quality Control Colposcopy & Case Management Committee.
- 2013 Actavis-Uteron Scientific Advisory Board, Prague, September 4
- 2013 Hologic, Scientific Advisory Board: STI Screening in Adolescents
- 2015-17 National Advisory Research Committee-Adolescent Health Consortium Project
- 2016-pr Antiva, Advisory Board, Therapeutic Treatment of CIN
- 2017 GSK, HPV Vaccine Immunology Advisory Board

- 2019-20 ASCCP/NIH Risk-Based Management Guidelines update on Management of Abnormal Cytology, Risk Modification Working Group co-chair
- 2020-pr. ASCCP/NIH Risk-Based Management Enduring Guidelines Committee member
- 2020-pr. Ontario (Canada) Cervical Screening Program's Screening and Colposcopy Recommendation Expert Panel member
- 2020-pr DSMB member: PATH sponsored Protocol # CVIA 087:A Phase 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity and Safety of Alternate Two-Dose Regimens of a Bivalent Human Papillomavirus (HPV) Vaccine (Cecolin<sup>®</sup>) Compared to a Licensed Quadrivalent HPV Vaccine (Gardasil<sup>®</sup>) in Healthy 9-14 Year-Old Girls in Low and Low-Middle Income Countries
- 2020-pr Lower Anogenital Squamous Terminology Standardization Project (LAST) expert panel member: College of American Pathologist
- 2021-pr Colaboración Evita Scientific Advisory Board member for NCI-funded collaborative project on prevention of HPV-related cancers among people living with HIV in the Caribbean and Latin America (ULACNet).

#### **HONORS AND SPECIAL AWARDS:**

- 1973-79 Six Year Honors Program in Medicine, Northwestern University School of Medicine
- 1984-85 STD Training Program Fellow, National Research Award: STD Training Program, NIAID, Grant # 1 T32 AI07234
- 1984-86 American Social Health Association Research Award, Sexually Transmitted Disease Research Project
- 1985-86 Affirmative Action Career Development Award, "Microbiologic Etiology of Endocervicitis Among Sexually Active Adolescent Females," University of California, San Francisco
- 1987-89 Howard Hughes Post Doctorate Fellowship Award Stanford University
- 1989 Young Investigator Award, Society for Adolescent Medicine
- 2005-15 Principal Investigator, National Cancer Institute, Merit Award: Natural History of HPV in Teens: R37 CA-051323-16, Total award: \$8,209,715 (1<sup>st</sup> 5 years)
- 2006 American Society of Colposcopy and Cervical Pathology: Distinguished Scientific Achievement Award
- 2007 UCSF Faculty Mentoring Program: Outstanding mentor award
- 2010 American Society for Colposcopy and Cervical Pathology, Meritorious Award of Service
- 2010 Chancellor's Award for the Advancement of Women, nominee, University of California San Francisco
- 2011 Chancellor's Award for the Advancement of Women, nominee, University of California San Francisco
- 2014 American Society for Colposcopy and Cervical Pathology, Distinguished Scientific and Meritorious Service
- 2014 American Academy of Pediatrics, Adele Hofmann Lifetime Achievement Award in

- Adolescent Medicine
- 2018 Honorary President, Eurogin 2018, International Multidisciplinary HPV Congress. Nov. 30<sup>th</sup>-Dec. 7<sup>th</sup>.
- 2019 American Society for Colposcopy and Cervical Pathology, Award of Merit for Screening for cervical cancer and Management of abnormal cytology in non-HIV immunocompromised women

SUMMARY OF SERVICE ACTIVITIES:

I had several leadership and service roles at UCSF before moving to UCLA. I had been the UCSF Chair for the Department of Pediatrics' Junior Faculty Grant Review Committee, which gives critical review to Junior Faculty for their 1<sup>st</sup> R- applications. I have also served as a member of junior faculty review board for the UCSF Department of Internal Medicine (COR). I was a member of the UCSF RAP and BIRCHW boards and was UCSF Vice-Chair for Clinical and Translational Research, Department of Pediatrics and Medical Director of Pediatric CTSI. At UCLA, I am Chair of the Clinical Trial Oversight Committee for the Department of Pediatrics, UCLA. I am a member of the UCLA CTSI Special Population Committee and perform CTSI K and R reviews for Junior faculty at UCLA. I am Associate Vice Chair for Clinical Research, Department of Pediatrics, and a member of the Executive Committee for the Children Discovery Institute, Department of Pediatrics. As for other non-university services, I have contributed to several Journals as reviewer and was on the Editorial Board for The Journal of Sexually Transmitted Disease. I have also served on several national committees including the American Cancer Society and was the President of the American Society for Colposcopy and Cervical Pathology in 2017-18. In the past, I have had been involved in several committees for the Society for Health in Adolescent Medicine (SAHM) which include the Membership Committee, Abstract Selection Committee, and Vaccine Committee and currently SAHM Annual Program Committee Member. Other past services include writing member of the National Board of Medical Examiners and American Board of Pediatrics, Adolescent Medicine Board. I have also served on several governmental committees including several NIH study sections, National Cancer Institute for the monograph on HPV epidemiology, NIH SPORE review committee and NCI PI internal review committee. I served as the Chair of the Adolescent Working Group for the ASCCP 2012 Guidelines for Abnormal Cytology and Histology Management and working group member of their HPV testing guideline committee and was co-chair of the Risk Modification Working Group for the 2019 ASCCP/NIH Risk-Based Management of Abnormal cytology and histology and continue to serve on the ASCCP/NIH Enduring Guidelines committee for Risk-Based Management. I served as the Chair of the PICSM working group on Adolescent cervical and screening management guidelines and participated in the American Cancer Society guidelines for cervical cancer screening in 2012 and 2019-20. I also served as chair of "Anal screening in women guidelines" and "Cervical Cancer Screening for non-HIV immunocompromised Working Group" for ASCCP. I have served on the Adolescent Committee within ACOG. I have also served on advisory boards for GSK and Merck for vaccine implementation and for Activis/Uteron, Hologic and Antiva. I am actively involved with Society for Health in Adolescent Medicine (SAHM) as member of their Awards and Program Committees. I also currently serve on several boards including Ontario Canada Cervical Screening Program's Screening and Colposcopy Recommendation Expert Panel, DSMB member of PATH sponsored protocol on the safety of a Chinese manufactured HPV vaccine, College of

American Pathologist, Lower Anogenital Squamous Terminology Standardization Project (LAST) and Colaboración Evita Scientific Advisory Board member for NCI-funded collaborative project on prevention of HPV-related cancers among people living with HIV in the Caribbean and Latin America (ULACNet). Internationally, I served as chair to numerous international organizations including Eurogin, Multidisciplinary Congress on Cervical Cancers and the International Papillomavirus Workshop. I co-hosted the 2005 International Papillomavirus clinical workshop and conference in Vancouver for over 1200 participants and was the immediate past honorary President of Eurogin 2018. I have been on the scientific committee for several of the International Papillomavirus Conferences and was Chair for the Clinical Science Track for the 2012 IPV meeting in Puerto Rico and am current chair for the Clinical Track for the 2020 IPV meeting in Barcelona. I was invited to serve on the Technical Workshop on Cellular Mediate Immunity to HPV by the WHO and service on a Think Tank of Cervical Cancer Vaccination as well as Global Cervical Cancer Prevention Board. I also participated in the Global Campaign on Ethics and Issues in Clinical trials of vaginal microbicides discussing issues relevant to adolescents.

**RESEARCH GRANTS:**

CURRENT

<p>EADI-15298 (PI Thiel) (Subcontract PI Moscicki)</p> <p>Disseminating cervical cancer screening guidelines through the DOTS-O patient education tool</p> <p><i>This study will disseminate the patient educational tool developed through the primary PCORI grant: Patient-Centered Outcomes Research Institute Randomized Trial to Increase Adherence to Cervical Cancer Screening Guidelines for Young Women</i></p>	<p>03/01/20-02/28/22 Subcontract Award: \$25,544</p>
<p>UL1TR001881 (Dubinett PI) NIH (NCATS)</p> <p>UCLA Clinical and Translational Science Institute (CTSI) Integrated Special Populations (ISP)</p> <p>The major goals of this project are to integrate special populations into UCLA’s research enterprise to ensure that breakthroughs are quickly translated to the benefit of society and its subpopulations. Role: Co-Investigator for ISP-</p>	<p>06/01/2016 – 05/31/2022 \$13,581 annual direct</p>



<p>UAZ2015-05-01 (PI Chow) (Moscicki site PI)</p> <p>NIH/ NCI/ University of Arizona</p> <p><i>A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-12 year-old girls.</i></p> <p><i>The overall objective of this Phase IIA trial is to determine the immunogenicity of a prime and deferred-booster dosing schedule of a nonavalent prophylactic HPV vaccine (GARDASIL 9) among 9-11 year-old girls.</i></p>	<p>09/01/2015 – 12/31/2021</p> <p>Total Subaward: \$1,423,720</p> <p>\$50,662 annual direct</p>
<p>3U01HD052102 (MPI:Williams, Chadwick, Hernández-Díaz and Jao) (subcontract PI: Moscicki)</p> <p>NIH/ DHHS/ Harvard University</p> <p>Oral Health Follow-up study in the PHACS Adolescent Master Protocol.</p> <p><i>This study will perform follow up oral health examination on PHIV and HEU patients who participated in the initial oral health study. The purpose is to examine risks for progression of periodontal disease in these patients. Dr. Moscicki is Consortium PI of this subcontract and PHACS M-PI of the oral health study.</i></p>	<p>08/1/2017- 4/30/2022</p> <p>Total Subaward: \$787,816</p> <p>\$307,386 annual direct</p>
<p>5 U01HDD052102 (M-PI Williams, Chadwick, Hernández-Díaz and Jao) (subcontract PI: Moscicki)</p> <p>NIH/ DHHS/ Harvard University</p> <p>“Pediatric HIV/AIDS Cohort Study Data and Operations Center: Assessment of HPV Association morbidity in HPV Vaccination PHIV adolescents and Young Adults in PHACS.”</p> <p><i>This study will examine factors associated with abnormal cervical cytology in PHIV-HPV vaccinated women. Dr. Moscicki is Consortium</i></p>	<p>08/01/2017-4/30/2022 (NCE)</p> <p>Total Subaward: \$409,106</p> <p>\$103,356 annual direct</p>

<p><i>PI of this subcontract and PHACS PI of the HPV study.</i></p>	
<p>584766 (PI Chow) (site PI Moscicki) NIH/ NCI/ University of Arizona HPV-Extended Followup Study</p> <p><i>The goal of this project is to continue follow up of subjects entered into UAZ2015-05-01 for additional years to examine the rate of decay of antibodies elicited by 2 doses of the HPV9 vaccine. Dr. Moscicki is co-investigator for study and site PI.</i></p>	<p>09/01/2020 – 8/31/2024 Total Subaward: \$467,883 \$205,175 annual direct</p>
<p>P01HD103133 (M-PI: Williams, Chadwick, Hernández-Díaz and Jao ) NIH/NICHD Pediatric HIV/AIDS Cohort Study (PHACS) 2020</p> <p><i>PHACS 2020 is a Program Project P01 grant, consisting of the following four support Cores: Scientific Administrative Core (SAC), Data Resources Core (DRC), Health Education and Community Core (HECC), and the Epidemiological and Statistical Methods Core (ESC) to provide scientific, site and cohort infrastructure, data management and analysis, health education and community input, as well as epidemiological and statistical support to four Research Projects. This multidisciplinary, interactive and synergistic P01 will address the most critical scientific questions for children, youth and young adults living with or exposed to perinatal HIV. Dr. Moscicki is a member of scientific leadership committee, the adolescent and young adult working committee and Chair of the site evaluation committee.</i></p>	<p>01/15/2021 - 07/31/2025 \$27,162 Annual Direct</p>
<p>P01HD103133-01S1 (M-PI: Williams, Chadwick, Hernández-Díaz and Jao ) NIH/NICHD Pediatric HIV/AIDS Cohort Study (PHACS) 2020</p> <p>Administrative supplement: PHACS 2020: The role of the microbiome,</p>	<p>01/15/2021 - 07/31/2023 \$128,341 annual direct</p>

<p>metabolome and inflammation in HPV persistence in HPVvaccinated women living with perinatal HIV infection.</p> <p>This supplement will compare the microbiome, metabolome and inflammatory biomarkers in women living with perinatal HIV who have HPV persistence vs those who have cleared. The study will use biorepository samples collected as part of PHACS protocol. Dr. Moscicki is the PHACS PI of the study and site PI to perform laboratory assays.</p>	
<p>HHSN261201200031I (Chow, Rangdale) NIH/NCI/University of Arizona</p> <p>Topical Therapies for Treatment of CIN 2-3</p> <p><i>This study is examining the efficacy of 5FU for the topical treatment of CIN 2-3. Dr. Moscicki will examine the effects of treatment on the microbiome and associated inflammatory markers and metabolites. These assays will be measured in her laboratory. Dr. Moscicki is PI of the subcontract.</i></p>	<p>1/1/2021 – 7/31/2022 Total Subaward: \$123,931</p>
<p>5R011A137680 NIH/NIAID (M-PI Hwang/Moscicki )</p> <p>Biological Vulnerability to Chlamydia trachomatis in adolescents and young women: the Complex Intersection of Cervicovaginal Microbiome, Cervical Maturation, and Mucosal Immunity”</p> <p><i>Purpose of study is using archival samples from the SF HPV cohort study to examine factors associated with chlamydia vulnerability</i></p>	<p>09/13/18-08/31/22 Total Award: \$2,232,134 \$442,648 annual direct</p>
<p>2R01HD082166-06A1 (Garber)</p> <p>NIH/UCSF</p> <p><i>Multi-center Randomized Controlled Trial of Refeeding in Anorexia Nervosa</i> <i>This study is a randomized controlled trials to examine the safety for refeeding persons diagnosed with atypical anorexia nervosa admitted for malnutrition with starting calories</i></p>	<p>04/01/2021-03/31/2026 \$11,272 annual direct</p>

<i>based on weight.</i> Role: site PI	
--	--

PAST

Principle Investigator University of California, San Francisco Academic Senate Research Grant Interaction of the Human Papillomavirus and Evolution of the Transformation Zone	1986-87 Total Award: not available
Principle Investigator University of California, University wide AIDS Task Force grant (PI) Psycho-social and Behavioral Risk Factors for AIDS	1987-89 Total Award: \$220,767
Principal Investigator Research Evaluation Allocation Committee Grant Award, School of Medicine, University of California, San Francisco The Natural History Study of Human Papillomavirus in Sexually Active Adolescents	1988-89 Total Award: not available
Principal Investigator AIDS Clinical Research Center Grant Award The Natural History Study of Human Papillomavirus in Sexually Active Adolescents	1988-90 Total Award: not available
Principal Investigator University of California University-wide AIDS Task Force Grant Evaluation of AIDS Intervention in High Risk Youth	1989-91 Total Award: \$59,926
Principal Investigator R01CA51323-01 NCI Natural History of HPV in Teens: Infection to Neoplasia	1990-95 Total Award: \$2,482,485
Principal Investigator RT 487 Tobacco-related Disease Research Program Grant Award The Effect of Tobacco on Cervical Neoplasia	1990-93 Total Award: \$959,786
Principal Investigator NIH Office of Research on Women's Health Administrative 1992-93 Supplement Award	1991-92 Total Award: \$50,000
Principal Investigator University of California, University wide AIDS Task Force Evaluation of AIDS Intervention in High Risk Youth	1991-92 Total Award: \$41,900
Principal Investigator NIH Office of Research on Women's Health Administrative Supplement Award	1992-93 Total Award: \$50,000

Principal Investigator Centers for Disease Control Efficacy of new dosing schedule for Hepatitis B vaccine	1994 Total Award: not available
Principal Investigator R01CA51323 NIH/NCI Natural History of HPV in Teens: Infection to Neoplasia - Competitive 5 year renewal	1995-00 Total Award: \$3,527,690
1U01HD/AI32830-01 (Member of Basic Science Group) NIH HIV and AIDS in Adolescents - National Cohort Study	1995-99 Total Award: \$666,422
Principal Investigator 1R03CA64328 NCI Propagation of Cervical Lymphocytes	1995-96 Total Award: \$72,437
Principal Investigator Office of Research on Women's Health Anal HPV infection in Young Women	1995-96 Total Award: \$50,000
Principal Investigator Supplement to #R01CA51323 NIH/NCI Cytotoxic Lymphocyte Response to HPV	1996-00 Total Award: \$337,387
Principal Investigator Supplement to #R01CA51323 Cytokine Expression of Local Cervical Lymphocyte to HPV.	1997-00 Total Award: \$297,212
Principal Investigator 3M Pharmaceuticals An Open-labeled, Multi-Center Safety and Efficacy Study of 5% Topical Imiquimod Cream in the Treatment of Visible External Genital/Perianal Warts in Male and Female Patients	1997 Total Award: not available
Principal Investigator 7RT-0195 University of California, San Francisco Tobacco-Related Disease Research Program Natural History of Tobacco Addiction in Adolescents	7/1/98 - 6/30/01 Total Award: \$500,000
Principal Investigator Qualitative Methods for Nicotine Addiction in Adolescents Robert Wood Johnson Foundation	1999-00 Total Award: \$60,000
Principal Investigator R01CA51323 NIH/NCI Natural History of HPV in Teens - Competitive 5 year renewal	2000-05 Total Award: \$6,560,707

Principal Investigator R01CA87905 NIH/NCI Natural History of CIN-2 in adolescents <i>This was a 5 year prospective study designed to: 1) examine the natural history of CIN-2 (cervical intra-epithelial lesions) subset of high grade squamous intra-epithelial lesions (HSIL) among adolescents, and 2) identify immunologic and behavioral factors associated with regression of CIN 2 lesions.</i>	2000-06 Total Award: \$3,036,848
U01 HD40533 (Co-Investigator) NICHD Adolescent Medicine Trials Network for HIV/AIDS, Adolescent Medicine Leadership Group	2001 Total Award: \$23,521
Principal Investigator 1U01 HD40506 NIH A San Francisco Street Youth Cohort: At Risk and HIV +  <i>To provide a cohort of HIV positive street involved youth into the Adolescent Medical Trials Unit (AMTU) to provide them with access to behavioral and clinical HIV research.</i>	4/16/01-2/28/13 Total Award: \$2,810,735 \$149,666 annual direct
21082 (PI: Padian, N) Co-Investigator, Melinda and Bill Gates Foundation, Preventing HPV by Protecting the Cervix <i>This study examined the use of a diaphragm in preventing HIV and HPV. Dr. Moscicki was a co-investigator</i>	2002-06 Total Award: \$13,539,227
2R01 CA077318-06A2 (PI: Goodman, M.) NIH Principal Investigator of Subcontract, Cohort Study of Diet and Duration of Cervical HPV <i>The major goal of this project was to examine interactions between local immune responses, nutrient deficiency and HPV persistence. Her role as PI of the subcontract was to perform all immune studies.</i>	6/3/05 - 3/31/10 Total Award: \$134,126
HHSN266200400074C (Co-Investigator) STICTG, Centers for Disease Control An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3% W/W SPL7013 Get (VivaGel™) in Healthy Adolescent Volunteers When Administered Twice Daily for 14 Days, <i>This study examined the safety and tolerability of 3% W/W SPL7013 Get (VivaGel™) in Healthy Adolescent Volunteers When Administered Twice Daily for 14 Days.</i>	2006 Total Award: \$2,744,406
RSG-06-180-01-msc (Principal Investigator– subcontract)	7/1/06-6/30/10

<p>CD8 T cell epitopes of High Risk HPV (PI: Mayumi Nakagawa) <i>The purpose of this project was to discover CD8 T-cell epitopes in the natural history of HPV cohort.</i></p>	<p>Total Award: \$104,305</p>
<p>Site Principal Investigator HPV-024 GlaxoSmithKline Phase IIb Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV 16 and/or HPV 18 cervical infection <i>The purpose of this study is to immunize the placebo group from the earlier phase of the randomized double-blinded placebo vaccine trial.</i></p>	<p>2007-2009 Total Award: \$37,733</p>
<p>109628 GlaxoSmithKline An open, phase II, multicenter study to assess the safety and immune response to a HPV-16/18 L1 VLP AS04 vaccine fourth dose in healthy, young, adult women in North America previously vaccinated with 3 doses of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 vaccine. <i>The purpose of this study was to process blood for storage and shipment to GSK for immune studies.</i> <i>Site PI</i></p>	<p>1/10/08 – 11/30/2009 Total Award: \$92,914</p>
<p>7 R01-AI065309-04 (Principal Investigator– subcontract) NIH Antimicrobial Peptides, Genital HSV &amp; HIV Co-Infection (PI: Betsy Herold) <i>The long-term objective of this project was to test leading candidate biosafety markers in ongoing or planned clinical trials with the goal of identifying those most predictive of microbicide safety for inclusion in future clinical trials.</i></p>	<p>6/15/08 - 2/28/10 Total Award: \$77,000</p>
<p>Principal Investigator Campbell Foundation HPV in Perinatally HIV-Infected Children and Adolescents <i>This was a cross-sectional study to examine prevalence of HPV infection in perinatally infected male and female children and adolescents who are nonsexually active and sexually active and to compare rates of infection to uninfected groups.</i></p>	<p>7/1/08 - 6/30/12 Total Award: \$80,022 \$25,630 annual direct</p>
<p>Principal Investigator E-track 110258 GlaxoSmithKline Safety and Immunogenicity of GSK Herpes zoster vaccine 1437173A in analogous hematopoietic cell transplant recipients (contract to process specimens)</p>	<p>6/4/09 – 9/30/11 Total Award: \$56,770</p>

<i>The purpose of this study was to process blood for storage and shipment to GSK for immune studies.</i>	
Principal Investigator UCSF RaP Epigenomic events of cervical tissue associated with oral contraceptive and cigarette use, C. trachomatis and human papillomavirus infections. <i>The aims of this project were to examine in cervical tissue epigenomic changes (as measured by methylation status) associated with oral contraceptive use and smoking cigarettes in subjects with and without HPV infection and to establish background variance and stability of methylation patterns over time.</i>	6/25/09 – 5/31/11 Total Award: \$30,300
Site Principal Investigator 8771-509 NICHD/ATN ATN 093: CDC-ATN/NICHD Testing and Linkage to Care Project <i>To identify HIV infected youth and link to care in SF Bay Area</i>	9/30/09 – 7/30/2012 Total Award: \$403,220
Site Principal Investigator 8182-509 NICHD/ATN ATN 096: Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults <i>The goal was to identify HIV infected Latino youth in the Bay Area through unique venues</i>	3/1/10 – 2/28/13 Total Award: \$247,497 \$52,715 annual direct
Principal Investigator RC1 AI86051-01 NIH/NIAID Mucosal immune response of the anus in women to HPV, intercourse, smoking and OCs <i>The goal of this application was to examine mucosal immune profiles in the anus of women to specific environmental exposures, specifically human papillomavirus (HPV), anal intercourse, tobacco and oral contraceptives (OC).</i>	9/23/10-8/31/12 \$205,903 annual direct
1 R01 CA140216-04 (PI: Rubinstein) NIH/NCI Nicotine Metabolism and the Development of Addiction in Adolescent Light Smokers <i>The aims of the study are to examine the association between the rate of nicotine metabolism and cigarette consumption over time in a prospective cohort of adolescent early/experimental smokers and to examine</i>	6/1/13 – 5/31/14 total (direct): \$1,488,703 \$297,741 annual direct



<p><i>the association between the rate of nicotine metabolism and the development of addiction in adolescent early/experimental smokers. Dr. Moscicki's role was co-investigator.</i></p>	
<p>1 R01 CA167421-01 (Wax) NIH/NCI Novel Coherence Imaging to Evaluate the Health of the Cervical Epithelium <i>The goal of this research project is to develop a novel coherence imaging platform for resolute and practical screening and diagnosis of the development of cervical intraepithelial neoplasia (CIN)-2, CIN-3, and cervical cancer. Dr. Moscicki is a co-investigator of this subcontract.</i></p>	<p>9/1/2013-8/31/2016 \$205,780 annual direct</p>
<p>U01 HD052102 (Seage) (Principal Investigator of subcontract) NIH/NICCHD Oral health among participants in the PHACS Adolescent Master Protocol (AMP) <i>This study examined and compared the oral health and microbiome of perinatally HIV infected and HIV-exposed uninfected children and adolescents of PHACS. Dr. Moscicki is the PI of this subcontract. Dr. Moscicki is lead investigator</i></p>	<p>8/1/14 – 7/31/15 Total (direct): \$283,720</p>
<p>U01 HD052102 (Seage) (Principal Investigator of subcontract) NIH/NICCHD Oral PHACS supplement: Immune Activation <i>This study focuses on examining the association between local and systemic immune responses and oral health/disease. Dr. Moscicki is lead investigator</i></p>	<p>8/1/14 – 7/31/15 total (direct): \$254,491</p>
<p>OPP1151304 BMGF: 01818000323 (Moscicki and Kamei: M-PIs) Bill and Melinda Gates Foundation: Challenge Grant Thermodynamic detection of cancer biomarkers on paper <i>The overall goal is to develop a point of care testing for cervical cancer screening. Dr. Moscicki is co-investigator</i></p>	<p>5/01/2016 – 10/31/2017 Total \$100,000 \$30,000 annual direct</p>
<p>R37 CA51323 (Principal Investigator) NIH/NCI Natural History of HPV in Teens: Merit Award <i>The major goal of this project is to examine the natural history of cervical HPV infection in youth, to examine the role of cytotoxic T cell lymphocytes and local cytokine production in eliminating HPV infection in the cervix.</i></p>	<p>2000-2017 Total Award: \$20,780,597</p>

<p>IMPAACT 1047 (co-investigator) - Safety And Immunogenicity Of Quadrivalent Human Papillomavirus (Type 6, 11, 18, L1 Virus-Like Particle [VLP]) (Gardasil) Vaccine in HIV-Infected Children &gt; 7 to &lt; 12 Years Of Age.</p> <p><i>This study focuses on examining durability of the quadrivalent HPV vaccine in HIV infected children. Dr. Moscicki is a co-investigator</i></p>	<p>2010-2017 Total Award: not available</p>
<p>Iris Cantor -UCLA Women Health Center / CTSI Marcia Leavitt Cervical Cancer Research Fund Pilot Grant Proposal (PI: Yang) A Novel Therapeutic Vaccine to Clear Early Cancerous Cervical HPV <i>The overall goal is to develop a systemic therapeutic vaccine against precancerous lesions. Role: Co-investigator</i></p>	<p>7/1/2016-6/30/2018 Total Award: \$75,000</p>
<p>20170820 (Chiu) Phase Diagnostics-SBIR Developing a highly sensitive, rapid, handheld vaginal swab test for the detection of Chlamydia trachomatis <i>The major goal of this grant it to develop a POCT for Chlamydia trachomatis. Role: Co-investigator</i></p>	<p>06/13/17-12/31/17 Total Award: \$1,150,000 \$7,910 annual direct</p>
<p>CD-1304-6551 (Moscicki) Patient-Centered Outcomes Research Institute Randomized Trial to Increase Adherence to Cervical Cancer Screening Guidelines for Young Women <i>This study will examine interventions for women and physicians in order to increase adherence to US guidelines for cervical cancer screening and triage of abnormal cytology.</i></p>	<p>7/1/2014 – 6/30/17 Total (direct): \$1,446,476 \$205,780 annual direct</p>
<p>California Community Foundation (Moscicki) “Randomized Trial to Increase Adherence to Cervical Cancer Screening Guidelines for Young Women” <i>The grant is to support of our program project coordinator to prepare and submit a paper for peer review on our trial</i></p>	<p>4/1/17-3/31/19 Annual Direct: \$21,283</p>
<p>Iris Cantor-UCLA Women Health Center / CTSI Marcia Leavitt Cervical Cancer Research Fund Pilot Grant Proposal (PI: Vidal) “Increasing human papillomavirus (HPV) vaccine uptake via General Health Messaging” <i>Overall goal is to increasing HPV vaccination in 11-12 years through general health messages via texting to Latina women. Role co-investigator.</i></p>	<p>8/1/2016-7/31/2019 Annual Direct: \$75,000</p>
<p>5U01 HD052104 (Van Dyke) NIH/NICCHD</p>	<p>8/01/2015 – 07/31/2020 \$27,474 annual direct</p>

<p>Perinatal HIV AIDS Cohort Study  This study will examine complication due to ARV exposure in utero and early childhood. Dr. Moscicki is a member of the Scientific Leadership Group.</p>	
<p>MR-15-327871 (Moscicki)  University of California Office of the President/Multi-campus Research Program; quality of life in type I diabetes mellitus  Cross-UC Campus Data Harmonization for Pediatric Outcomes  <i>The overall goals of this proposal are to create valid templates for collection of patient outcomes data during clinical care visits that then can be extracted and de-identified for research and quality control across all 5 UC campuses.</i></p>	<p>1/1/2015 - 6/30/2019  Total (direct): \$1,419,580  \$293,690 annual direct</p>
<p>MRP-18-611873 (Moscicki)  UC Office of the President/ MRPI   Quality of Life in patients with type I diabetes mellitus  Purpose of the study is to examine the impact of quality of life, substance use and mental health on diabetes health.</p>	<p>09/01/2018-08/31/2020 (NCE)  \$250,000 annual direct</p>
<p>R01HD082166-01 (Garber)  NIH/NICHD/Multicampus Sub from UCSF  Multi-center Randomized Controlled Trial of Refeeding in Anorexia Nervosa  <i>The purpose of this multi-center RCT is to compare short- and long-term recovery in adolescents hospitalized with a secondary to malnutrition and refed on two refeeding protocols with varying caloric levels and rates of advancement. Dr. Moscicki is a consultant</i></p>	<p>7/1/2015 - 6/30/2020  \$10,107 annual direct</p>
<p>No fund number (Moscicki)  I-ACT/DHHS-FDA  INSTITUTE FOR ADVANCED CLINICAL TRIALS FOR CHILDREN SITE AGREEMENT  <i>The Site Champion will work closely with Clinical Research Directors/Administrators (those with oversight of clinical trials units, study coordinators, research nursing, etc.) to provide leadership and proactive vision setting within and beyond the site.</i></p>	<p>09/01/2018-02/11/2021  Total Award: \$7,500  \$4,808 annual direct</p>

**LECTURES AND PRESENTATIONS:**

*International:*

2003 “Translating immunology into practice,” Eurogin: Preventing and Controlling Cervical Cancer in the New Millennium; Paris, April 13-16

- 2003 "When to start screening," Eurogin: Preventing and Controlling Cervical cancer in the New Millennium; Paris, April 13-16
- 2003 "CD4 T cell responses in natural history studies," Symposium on Human Papillomavirus: vaccine and immunotherapies, Cambridge, England, July
- 2004 "HPV infections in adolescents," 21st HPV International Conference and Clinical Workshop in Papillomavirus, Mexico City, Feb 20-26
- 2004 "Immune Responses to HPV," 21st HPV International Conference and Clinical Workshop in Papillomavirus, Mexico City, Feb 20-26
- 2004 "Problems of Adolescent Cervical Cancer Screening and Prevention," American Society for Colposcopy and Cervical Pathology 2004 Biennial Meeting, Lake Buena Vista, FL, March 15-19
- 2004 "Natural history of HPV-what's new," The Royal Women's Hospital, International guest speaker, Melbourne Australia July, 17th
- 2004 "Cervical Cancer not yet beaten and at what cost," The Royal Women's Hospital, International guest speaker, Melbourne Australia July, 17th
- 2004 "Is there any future for cytology in screening," The Royal Women's Hospital, International guest speaker, Melbourne Australia July, 17th
- 2004 "Management of immune compromised HPV infected women," The Royal Women's Hospital, International guest speaker, Melbourne Australia July, 17th
- 2004 "Cell mediated immunity and clearance of HPV: comparison of PB IFN gamma elispot and cervical cytokine protein and RT-PCR expression" Eurogin 2004 International Expert Meeting HPV infection and Cervical Cancer Prevention: Priorities and New Directions-Physicians, Patients and Public Health Issues, Nice France, October 21-23
- 2005 Technical Workshop on Cellular Mediated Immunity to HPV: Prospects for Vaccine Development, World Health Organization, Geneva, April 18-19.
- 2005 "HPV Testing in Diagnosis and Management; Screening in Adolescents," 22<sup>nd</sup> International Papillomavirus Conference and Clinical Workshop, Vancouver, Canada, April 30-May 6
- 2005 "Natural History of HPV in Young Women: Immune Correlates and New Guidelines for HPV Testing and Follow-up of CIN-1," Scientific Conference: HPV – New Directions in Screening of Cervical Cancer, Polish Society for Colposcopy and Cervical Pathology, Krakow, Poland, June 1<sup>st</sup>.
- 2006 "Systemic And Mucosal Immune Responses Important to HPV Clearance: Results From A Cohort Study," European Research Organization on Genital Infection and Neoplasia, 6<sup>th</sup> International Interdisciplinary Conference, Paris, France, April
- 2006 "Years sexually active and Oral Contraceptives are a risk for CIN 3 in adolescents and young women," 23<sup>rd</sup> International Papillomavirus Conference 2006, Prague, September 1-7
- 2006 "HPV and Cervical Cancer," 3<sup>rd</sup> International Forum on Vaccines, HPV Vaccines and Cervical Cancer, Instituto Catalan de Oncologia (ICO) and Fundacion para el Estudio de la Infeccion (FEI), Universidad Complutense de Madrid, Madrid, Spain, October 19.
- 2007 "CIN management guidelines in adolescents and young women." Polish Society of HPV Prevention, Warsaw, April 2007
- 2007 The Prophylaxis of cervical cancer and other HPV-associated diseases in the era of

- anti-HPV vaccine.” Polish Society of HPV Prevention, Warsaw, April 2007
- 2007 “Understanding the HPV natural history study: Latency and persistence.” Eurogin 2007: New Strategies of Cervical Cancer Prevention – The Reality of HPV Vaccines, Monte-Carlo, Monaco, October 2007
- 2007 “Innate and Adaptative Immune Responses to HPV.” Eurogin 2007: New Strategies of Cervical Cancer Prevention – The Reality of HPV Vaccines, Monte-Carlo, Monaco, October 2007
- 2007 “Local immune responses to STDs and vaginal microbicides.” 20<sup>th</sup> Annual Meeting of the Japanese Society for Sexually Transmitted Diseases, Tokyo, Japan, December 1-2.
- 2008 “Abnormal Paps In Adolescents: What To Do And What Not To Do.” Eurogin 2008: Joining Forces for Cervical Cancer Prevention, Nice, France, November 12-15
- 2008 “Repeated Infections In Young Women: How Common Do They Occur?” Eurogin 2008: Joining Forces for Cervical Cancer Prevention, Nice, France, November 12-15
- 2008 “HPV Co-Infection: Current Knowledge, Incidence, Interaction and Practical Issues.” Eurogin 2008: Joining Forces for Cervical Cancer Prevention, Nice, France, November 12-15
- 2008 “Mucosal Immune Responses to HPV: Role of TLRs and Cytokines. Eurogin 2008: Joining Forces for Cervical Cancer Prevention, Nice, France, November 12-15.
- 2009 “Rate of and risks for second infections in young women.” The 25th International Papillomavirus Conference 2009, Malmö, Sweden, May 8-14
- 2010 “HPV associated disease in special populations: teenagers” Eurogin 2010 Congress - Cervical Cancer Prevention: 20 Years of Progress and A Path to the Future, Monte Carlo, Monaco, February 17-20
- 2010 “Issues related to best age to vaccinate” Eurogin 2010 Congress - Cervical Cancer Prevention: 20 Years of Progress and A Path to the Future, Monte Carlo, Monaco, February 17-20
- 2010 “Managing adverse events in teens” Eurogin 2010 Congress - Cervical Cancer Prevention: 20 Years of Progress and A Path to the Future, Monte Carlo, Monaco, February 17-20
- 2010 “The End of Pap Smear Screening in Adolescents.” The Society for Adolescent Health and Medicine Annual Meeting: Toronto, Canada April 7-10, 2010
- 2010 “Anal Cytology: Who, How, and Then What?” The Society for Adolescent Health and Medicine Annual Meeting: Toronto, Canada April 7-10, 2010
- 2010 “Repeated Infections in Young Women: How Common Do They Occur?” X International Workshop on Lower Genital Tract Pathology HPV Disease 2010 A.D.: Coming into the Light – Viareggio, 6th-8<sup>th</sup>, May 2010
- 2010 “Natural History of HPV in Women: Our Current Understanding.” X International Workshop on Lower Genital Tract Pathology HPV Disease 2010 A.D.: Coming into the Light – Viareggio, 6th-8<sup>th</sup>, May 2010
- 2010 “Men and Cervical Cancer.” X International Workshop on Lower Genital Tract Pathology HPV Disease 2010 A.D.: Coming into the Light – Viareggio, 6th-8<sup>th</sup>, May 2010
- 2010 “Guidelines for Pap Testing, HPV Testing, and Colposcopy.” X International Workshop on Lower Genital Tract Pathology HPV Disease 2010 A.D.: Coming into the Light – Viareggio, 6th-8<sup>th</sup>, May 2010
- 2010 “To Screen or Not to Screen: Cervical Cancer Screening and Management Issue In

- Adolescents.” The Society of Obstetricians and Gynaecologists of Canada Annual Clinical Meeting, Montreal, Canada, June 2-6
- 2010 “Natural History of HPV Infection in Younger Women: Implications for Screening, Follow-Up, and Treatment.” IPV: International Papillomavirus Meeting, Montreal, Canada, July 3-8
- 2010 “Men and Cervical Cancer.” XX International Meeting on Cervical Cancer Prevention: New Trends in the Vaccination Era. Mexico City, Mexico Nov 4-6
- 2010 “Natural History of HPV in Young Women: Our Current Understanding.” XX International Meeting on Cervical Cancer Prevention: New Trends in the Vaccination Era. Mexico City, Mexico Nov 4-6
- 2010 “Guidelines for Pap Testing, HPV Testing, and Colposcopy in Adolescents.” XX International Meeting on Cervical Cancer Prevention: New Trends in the Vaccination Era. Mexico City, Mexico Nov 4-6
- 2010 “Repeated Infections in Young Women: How Common Do they Occur?” XX International Meeting on Cervical Cancer Prevention: New Trends in the Vaccination Era. Mexico City, Mexico Nov 4-6
- 2011 “Age Specific HPV Infection and Disease: Adolescents and Young Women.” Eurogin 2011 - HPV-associated Diseases and Cancer: From Reality Now to the Future, Lisbon, Portugal May 8-11
- 2011 “Viral Latency vs Recurrence New Infection.” Eurogin 2011 - HPV-associated Diseases and Cancer: From Reality Now to the Future, Lisbon, Portugal May 8-11
- 2011 “Local Immune Responses to HPV and Neoplasia.” Eurogin 2011 - HPV-associated Diseases and Cancer: From Reality Now to the Future, Lisbon, Portugal May 8-11
- 2011 “Adolescents: Prevention, Screening, and Management.” 14th World Congress of Cervical Pathology and Colposcopy, Rio De Janeiro, Brazil, July 4-7
- 2011 “Natural History of HPV Infection in Adolescents and Young Women.” 14th World Congress of Cervical Pathology and Colposcopy, Rio De Janeiro, Brazil, July 4-7
- 2011 “Clinical Use of Biomarkers: What Are We Looking For?” 27th International Papillomavirus Conference and Clinical Workshop, Berlin, September 17-22
- 2012 "Screening in Women Under 25 Years of Age: Why?" HPV: the Global Battle: XI International Workshop on Lower Genital Tract Pathology. Rome, Italy, April 19-21
- 2012 "Natural History of HPV Infection in Adolescents and Women." HPV: the Global Battle: XI International Workshop on Lower Genital Tract Pathology. Rome, Italy, April 19-21
- 2012 "Can Treatment of CIN Result in Immune Response that Results in Regression and Protection?" HPV: the Global Battle: XI International Workshop on Lower Genital Tract Pathology. Rome, Italy, April 19-21
- 2012 "HPV Cross-Protection: What is the Additional Clinical Benefit?" HPV: the Global Battle: XI International Workshop on Lower Genital Tract Pathology. Rome, Italy, April 19-21
- 2012 "Duration of Protection: What Happens When Immunity Wanes?" HPV: the Global Battle: XI International Workshop on Lower Genital Tract Pathology. Rome, Italy, April 19-21
- 2012 “Anal Cancer Screening in Women.” Girls and Adolescent Health: Pediatric and Adolescent Gynecology Society International Scientific Conference, Vilnius, Lithuania, May 4

- 2012 “Adolescents: Where the HPV Story Starts?” Girls and Adolescent Health: Pediatric and Adolescent Gynecology Society International Scientific Conference, Vilnius, Lithuania, May 4
- 2012 “PCOS in Adolescents: Is it All the Same?” Girls and Adolescent Health: Pediatric and Adolescent Gynecology Society International Scientific Conference, Vilnius, Lithuania, May 4
- 2012 “Opportunities for the Prevention of Heterosexual Transmission.” Eurogin 2012 International Multidisciplinary Congress, Prague, July 8-11
- 2012 “HPV Vaccines in HIV-infected Individuals.” Eurogin 2012 International Multidisciplinary Congress, Prague, July 8-11
- 2012 “Reactivation vs. New HPV-16 Detection.” Eurogin 2012 International Multidisciplinary Congress, Prague, July 8-11
- 2012 “The Human Papillomavirus in Teenagers.” College of Mexican Specialists in Gynecology and Obstetrics, Mexico City, November 28
- 2012 “Analysis of the Rate of Regression of Cervical Intraepithelial Neoplasia in Young Women and Teenagers.” College of Mexican Specialists in Gynecology and Obstetrics, Mexico City, November 28
- 2012 “HPV Vaccination in Teenagers: An Expert’s Opinion.” College of Mexican Specialists in Gynecology and Obstetrics, Mexico City, November 28
- 2012 "Age to Start Screening: U.S. and European Perspectives." 28th International Papillomavirus Conference, San Juan, Puerto Rico, Nov 30 - Dec 6
- 2012 "Welcome to Clinical Immunology." 28th International Papillomavirus Conference, San Juan, Puerto Rico, Nov 30 - Dec 6
- 2012 "Natural History of CIN 2: Is It Real Or Is It A Myth?" 28th International Papillomavirus Conference, San Juan, Puerto Rico, Nov 30 - Dec 6
- 2013 “How to Face Colposcopy Limitations.” 15th Congress of Public Health Research, National Institute of Public Health, Cuernavaca, Mexico, March 7
- 2013 “Anal Cancer Screening in Women.” Congreso Internacaional de Colposcopia, Mexico City, May 2-4
- 2013 “HPV in Adolescents and Young Women: Natural History and Guidelines for Screening Treatment.” Congreso Internacaional de Colposcopia, Mexico City, May 2-4
- 2013 “Natural History of HPV Cervical, Oral and Anal Infections.” Congreso Internacional de Colposcopia, Mexico City, May 2-4
- 2013 "CIN 2: Reality or Myth?" Eurogin 2013 International Multidisciplinary Congress, HPV at a Crossroads: 30 Years of Research and Practice, Florence, Italy, November 3-6
- 2013 "HPV Latency at the Cervix and Other Anatomic Sites." Eurogin 2013 International Multidisciplinary Congress, HPV at a Crossroads: 30 Years of Research and Practice, Florence, Italy, November 3-6
- 2013 "Heterosexual Transmission: Results from a Short Term Observational Study." Eurogin 2013 International Multidisciplinary Congress, HPV at a Crossroads: 30 Years of Research and Practice, Florence, Italy, November 3-6
- 2013 "Announcing HPV Infection: How to Deal with the Patient." Eurogin 2013 International Multidisciplinary Congress, HPV at a Crossroads: 30 Years of Research and Practice, Florence, Italy, November 3-6

- 2014 “Human Papillomavirus Prevention Infection, Immunology and Vaccine Strategies.” FHI 360: The Science of Improving Lives, Cambodia, March 3
- 2014 "Epidemiology of HPV and its Role in Cervical Cancer (A.K.A. The Natural History of HPV)" M'ekelle University, M'ekelle, Ethiopia, October 8
- 2014 "Overview of virus associated oral cancers in HIV infected persons." 7th World Workshop on the Mouth and AIDS: Lessons Learned and Emerging Challenges in Global Oral Health, Hyderabad, India, November 6-9
- 2015 “Immune responses, regression, and persistence of HPV 16 & 18.” Eurogin 2015 International Multidisciplinary Congress, Sevilla, Spain, February 4-7
- 2015 “Managing 21-24 year old women with CIN.” Eurogin 2015 International Multidisciplinary Congress, Sevilla, Spain, February 4-7
- 2015 “The environment of HPV.” Eurogin 2015 International Multidisciplinary Congress, Sevilla, Spain, February 4-7
- 2015 “Immunology of regression vs persistence.” Eurogin 2015 International Multidisciplinary Congress, Sevilla, Spain, February 4-7, 2015
- 2015 “HPV vaccination in the immunocompromised.” Eurogin 2015 International Multidisciplinary Congress, Sevilla, Spain, February 4-7
- 2015 “CIN 2 - Where are we now: do we treat it or not?: Clinical perspective.” XXI International Workshop of Lower Genital Tract Pathology, Rome, Italy, March 5-7
- 2015 “HPV infection and cervical cancer: what do the natural history studies tell us about the mechanisms of progression vs regression and does this help clinical decision making?” XXI International Workshop of Lower Genital Tract Pathology, Rome, Italy, March 5-7
- 2015 “Children and Adolescents Positive for HPV: Implications to the Clinics” 30<sup>th</sup> International Papillomavirus Conference & Clinical Workshop (HPV 2015), Lisbon Portugal, September 17-21
- 2015 “Cervical Maturation and Oncogenic Susceptibility” 30<sup>th</sup> International Papillomavirus Conference & Clinical Workshop (HPV 2015), Lisbon Portugal, September 17-21
- 2015 “Vulnerability of the Normal Transformation Zone” 30<sup>th</sup> International Papillomavirus Conference & Clinical Workshop (HPV 2015), Lisbon Portugal, September 17-21
- 2016 “HPV Persistence and the Human Microbiome” Eurogin 2016 International Multidisciplinary Congress, Salzburg, Austria, June 15-18
- 2016 “Genital Warts and HPV Detection in Children” Eurogin 2016 International Multidisciplinary Congress, Salzburg, Austria, June 15-18
- 2016 “Cervical Cancer Screening in Young Women” Congreso Argentino De Patologia Del Tracto Genital Inferior Y Coloscopia, Buenos Aires, Argentina, September 22-24
- 2016 “HPV Vaccine Updates: Real World Efficacy and Number of Doses” Congreso Argentino De Patologia Del Tracto Genital Inferior Y Coloscopia, Buenos Aires, Argentina, September 22-24
- 2016 “Management of Abnormal Cytology in Young Women” Congreso Argentino De Patologia Del Tracto Genital Inferior Y Coloscopia, Buenos Aires, Argentina, September 22-24
- 2016 “Transmission of HPV in Young Heterosexual Couples” Congreso Argentino De Patologia Del Tracto Genital Inferior Y Coloscopia, Buenos Aires, Argentina, September 22-24
- 2016 “Immune Responses to HPV: What Creates Protection.” Congreso Argentino De



- Patologia Del Tracto Genital Inferior Y Coloscopia, Buenos Aires, Argentina, September 22-24
- 2016 “HPV infection in Adolescent and Young Women, consequences for the future” XVI Congreso De La Sociedad Cubana di Obstetricia Y Ginecologia, VI Congreso Cubano de Ginecologia Infanto Juvenil y Salud Reproductiva del Adolescente. Havana, Cuba, October 4-8
- 2016 “US Experiences in HPV Vaccination” XVI Congreso de la Sociedad Cubana di Obstetricia Y Ginecologia, VI Congreso Cubano de Ginecologia Infanto Juvenil y Salud Reproductiva del Adolescente Havana, Cuba, October 4-8
- 2016 “Natural History of HPV Infection and Triggers of Cervical Carcinogenesis: How Has The Evidence Evolved” Annual Course on Colposcopy and Cervical Pathology, Ioannina, Greece, November 11th-13th
- 2017 “ HPV Persistence and Microbiome” IPV Conference 2017. Captetown, South Africa, February 28th-March 4th
- 2017 “ HPV4 Vaccine Immunogenicity” IPV Conference 2017. Captetown, South Africa, February 28th-March 4th
- 2017 “Anal Infection and Diseases” Eurogin 2017. Amersterdam, October 8th-11th
- 2017 “ HPV Persistence and Microbiome” Eurogin 2017. Amersterdam, October 8th-11th
- 2017 “Vaccination for Sexually Abused Children” Eurogin 2017. Amersterdam, October 8th-11th
- 2017 “High resolution anoscopy: Screening of Anal disease in women” Congress of Brazil of Lower Genital Tract Pathology and Coloscopy 2017. Rio Grande do Sul, Brazil. October 18th-21st
- 2017 “How long do you want to keep track of CIN1?” Congress of Brazil of Lower Genital Tract Pathology and Coloscopy 2017. Rio Grande do Sul, Brazil. October 18th-21st.
- 2017 “Primary HPV vaccine prevention: Update and future prospects.” Congress of Brazil of Lower Genital Tract Pathology and Coloscopy 2017. Rio Grande do Sul, Brazil. October 18th-21st
- 2017 “Screening in Adolescents and Young Women: Changes after vaccine introduction” Congress of Brazil of Lower Genital Tract Pathology and Coloscopy 2017. Rio Grande do Sul, Brazil. October 18th-21st
- 2018 “Natural History of HPV in “screening” age women: bu what is “screening age?”) International Workshop on Lower Genital Tract Pathology. Rome, Italy. April 12th-13th
- 2018 “The effect of IUD on acquisition and clearance of HPV” International Workshop on Lower Genital Tract Pathology. Rome, Italy. April 12th-13th
- 2018 “The Role of the Vaginal Microbiome in HPV infection and disease” International Workshop on Lower Genital Tract Pathology. Rome, Italy. April 12th-13th
- 2018 “HPV in non-HIV infected immunocompromised men and women: natural history and clinical implications for screenng.” International Workshop on Lower Genital Tract Pathology. Rome, Italy. April 12th-13th
- 2018 “The role of cytology and HPV genotyping in screening for anal cancer” International Workshop on Lower Genital Tract Pathology. Rome, Italy. April 12th-13th
- 2018 “Natural history of HPV infection and triggers of Cervical Carcinogenesis: How has the Evidence evolved.” BSCCP (British Society for colposcopy and cervical pathology) 2018, Annual Scientific Meeting, Manchester Central, UL 30th April -2<sup>nd</sup> May.
- 2018 “HPV Infections in Adolescents” 8th Congress of Iranian Society of Gynecology

- Oncology. Tehran, Iran May 2nd-4th
- 2018 “Advanced Colposcopy Course” 8th Congress of Iranian Society of Gynecology Oncology. Tehran, Iran May 2nd-4th
- 2018 “HPV screening and Disease in Immunocompromised Women” 32nd International Papillomavirus Conference, Sydney, Australia October 2-6
- 2018 “Child Abuse and HPV” Eurogin 2018. Lisbon, Portugal. Nov. 30<sup>th</sup>-Dec 7<sup>th</sup>.
- 2018 “HPV Persistence and Clearance Related to Microbiota” Eurogin 2018. Lisbon, Portugal. Nov. 30<sup>th</sup>-Dec 7<sup>th</sup>.
- 2019 “Cervical Cancer Screening in Immunocompromised Women” Chinese Society of Colposcopy and Cervical Pathology. Shenzhen, China. May 10<sup>th</sup>-12<sup>th</sup>.
- 2019 “HPV Vaccination in Adolescents” Colposcopia Cognitiva Evolucionando en la practica. Mexico City, Mexico. May 17<sup>th</sup>.
- 2019 “The natural history of CIN in young women” Colposcopia Cognitiva Evolucionando en la practica. Mexico City, Mexico. May 17<sup>th</sup>.
- 2019 “Natural history of HPV infection and triggers of cervical carcinogenesis.” VI Columbian Colposcopy Congress. Cartagena de Indias, Colombia. May 23<sup>rd</sup>-May 25<sup>th</sup>.
- 2019 “Role of the vaginal microbiota in the progression or regression of untreated CIN 2 lesions.” VI Columbian Colposcopy Congress. Cartagena de Indias, Colombia. May 23<sup>rd</sup>-May 25<sup>th</sup>.
- 2019 “Cervical cancer screening in Non-HIV immunosuppressed women.” VI Columbian Colposcopy Congress. Cartagena de Indias, Colombia. May 23<sup>rd</sup>-May 25<sup>th</sup>.
- 2019 “Primary HPV vaccine prevention: Update and future prospects” Congress on Pediatrics and Adolescent Gynaecology. Onogynaecology. Oncofertility. Vilnius, Lithuania. October 11, 2019.
- 2019 “Natural history of HPV infection and cervical carcinogenesis: Impact on CIN 2/3 management in young women” Congress on Pediatrics and Adolescent Gynaecology. Onogynaecology. Oncofertility. Vilnius, Lithuania. October 11, 2019.
- 2019 “Updates on optimal cervical cancer screening among HIV infected women and other immunocompromised women.” Eurogin 2019: Accelerating Detection and Elimination of HPV and Related Cancers; Monaco. December 4<sup>th</sup>-7<sup>th</sup>, 2019.
- 2019 “Anal HPV and anal squamous intraepithelial lesions in women-a global perspective.” Eurogin 2019: Accelerating Detection and Elimination of HPV and Related Cancers; Monaco. December 4<sup>th</sup>-7<sup>th</sup>, 2019.
- 2019 “Immunocellular action mechanisms of HPV and clinical consequences of laser rejuvenation.” Eurogin 2019: Accelerating Detection and Elimination of HPV and Related Cancers; Monaco. December 4<sup>th</sup>-7<sup>th</sup>, 2019.
- 2020 “Natural History of HPV: implications for control” 28<sup>th</sup> World Congress on Controversies in Obstetrics, Gynecology, and Infertility. Nov 19, 2020 Virtual
- 2021 “HPV Latency is it real and does it matter?” International Papillomavirus Educational webinar series 2021: February 17, 2021
- 2021 “Natural History of HPV infection latency and clearance” 17th World Congress for Cervical Pathology and Colposcopy: Eliminating Cervical Cancer-Call for Action July 1-5, 2021 Virtual
- 2021 “Changes in cervical cancer screening from age 21 to 25 years: are we ready?” 45th Society of Gynecology and Obstetrics of the Rio de Janeiro Congress and Exchanging Ideas XXIV June 22-24, 2021 (virtual)

2021 Debate: is it time to change cervical screening practices in women vaccinated against HPV—Pro. International Papillomavirus Conference, November 15-19, 2021.

*National and Regional*

- 1985 "Sexually Transmitted Disease Update: Bacterial Vaginosis, C.trachomatis, Herpes Simplex Virus, Pelvic Inflammatory Disease, and Mucopurulent Cervicitis." Department of Public Health, San Francisco, CA
- 1986 "Sexually Transmitted Disease Screening in Adolescents." Valley Medical Center, Fresno
- 1986 "Reproductive Health in the Adolescent Female: the Normal Process." Adolescent Medicine Symposium sponsored by McNeil Consumer Products Co., Phoenix, AZ
- 1986 "Bacterial Vaginosis and C.trachomatis Infections in Females." Universite Laval, Quebec City
- 1986 "Vaginitis." Symposium for VD Hotline, American Social Health Association
- 1986 "Reproductive Health: The Normal Process and Implications for Anticipatory Guidance." Pediatric Grand Rounds, University of California, San Francisco
- 1986 "Normal Reproductive Health in Adolescents." Santa Rosa Community Hospital, Family Practice Grand Rounds
- 1986 "Human Papilloma Virus Infections in Adolescents." University of California, San Francisco, Pediatric Grand Rounds
- 1986 "Pelvic Inflammatory Disease and Human Papilloma Virus Infections." Letterman Army Medical Center, Pediatric Grand Rounds
- 1986 Workshop: "Sexually Transmitted Diseases." Conference on the Family: Understanding Common Adolescent Problems. Division of Family and Community Medicine, University of California, San Francisco
- 1986 "Chlamydia Trachomatis Update." Symposium on Chlamydia and Herpes. Northern Division of the California Public Health Association
- 1986 "Human Papilloma Virus and Bacterial Vaginosis." Grand Rounds, Valley Medical Center, Fresno, CA
- 1987 "Chlamydial Infections in Women" for Family Planning Clinics, Department of Public Health, San Francisco
- 1987 "Biosocial Aspects of Sexually Transmitted Diseases: Adolescents and STD's." "Human Biology, 128. Undergraduate Course, Stanford University.
- 1987 "Biologic Maturation and Assessment of the Cervix" Dept. of Medical Microbiology, UCSF
- 1988 "Sexually Transmitted Disease Update and New Perspectives On an Old STD: Human Papilloma Virus." Grand Rounds, Children's Hospital of San Francisco
- 1988 "Human Papillomavirus: Update": Department of Health, San Francisco
- 1988 "Prevention Prognosis Symposium" Guest Lecturer in Adolescent Health Issues, supported by Medical McCarthy Marketing; The New Health Centers/Primary Prevention Programs, Los Angeles, CA
- 1988 "Clinical and Laboratory Diagnosis of Human Papillomavirus," Oakland Children's

- Hospital Grand Rounds. Oakland, CA
- 1988 "Human Papillomavirus in Young Women." Santa Rosa Kaiser Permanente Inc., Grand Rounds, Santa Rosa, CA
- 1989 "Diagnosis of Human Papillomavirus Infection in Adolescents." Marin General Hospital Grand Rounds, Kentfield, CA
- 1989 "Talking With Teens About Sex and Its Consequences: Sexually Transmitted Diseases, AIDS and Pregnancy." Community Health Talks, University of California, San Francisco
- 1989 "Human Papillomavirus Infections in Adolescents" Youth's Dilemma. American College of Physicians Annual Meeting, San Francisco, CA
- 1989 "Human Papillomavirus: What does it cause?" Grand Rounds. Department of Pediatrics, University of California, San Francisco
- 1990 "Human Papillomavirus" Fourth Annual Conference on Pediatrics and Adolescent Gynecology. Costa Mesa, CA
- 1990 "Human Papillomavirus Infection in Children and Adolescents" workshop. National Society for Pediatric and Adolescent Gynecology Annual Meeting, Pasadena, CA
- 1990 "Adolescent Suicide", Invited Speaker. Department of Pediatrics, University of California, San Diego. CA
- 1990 "Human Papillomavirus: Clinical Diagnosis and Treatment. 11th Annual Conference for Pediatric Primary Care, National Association of Pediatric Nurse Associates and Practitioners, San Francisco, CA
- 1990 "Diagnosis of Human Papillomavirus", Update for Practitioners, Roche Labs. Sacramento, CA
- 1990 "Human Papillomavirus Infections in Adolescents", Pediatric Clinical Grand Rounds, John Muir Hospital, Walnut Creek, CA
- 1990 "Human Papillomavirus in Adolescents", Sexually Transmitted Disease Update: San Francisco Department of Public Health, STD Prevention/Training Center, San Francisco, CA
- 1990 "Update on Sexually Transmitted Disease Infections", Grand Rounds, Children's Hospital of San Francisco
- 1990 "Human Papillomavirus: Female Urology and Urinary Tract Infection", Postgraduate Course Speaker, University of California, San Francisco
- 1990 "Interviewing the Adolescent Patient," UCSF Adolescent Health Elective, University of California, San Francisco
- 1991 "Papillomavirus Infections in Adolescents - What does the future hold" and "Sexually transmitted diseases in adolescents other than papillomavirus", Adolescent Medicine for the Practitioner: 1991, Scripps Clinic and Research Foundation, San Diego, CA
- 1991 "HPV in Adolescent Females: Prevalence Risk Factors and Cytology", Invited Speaker, Western Society for Pediatric Research, Carmel, CA
- 1991 "Human Papillomavirus and Other Sexually Transmitted Diseases in Adolescents", Medical Update Conference for Physicians, Planned Parenthood, Alameda/San Francisco, Oakland, CA
- 1991 "Human Papillomavirus Infections", Grand Rounds, Oakland Naval Hospital, Oakland, CA
- 1991 "High Risk Youth in STD Clinics", Education and Behavior Modification Conference: An Assessment of HIV Prevention Programs, sponsored by UCLA, San Francisco, CA

- 1992 "AIDS and Adolescents", Pediatric Grand Rounds, Fresno Valley Community Medical Center, Fresno, CA
- 1992 "What's New in Diagnosis and Treatment of Human Papillomavirus, Syphilis and C.trachomatis Infection in Women", 5th Annual Obstetrics and Gynecology Symposium, Memorial Hospital Association, Modesto, CA
- 1992 "Human Papillomavirus Infections: Children's Diagnosis and Treatment, Oakland Children's Hospital, 22nd Annual Fall Conference jointly sponsored with the Northern California of the American Academy of Pediatrics
- 1993 Chair: Adolescent Medicine/General Pediatrics Session for Western Pediatric Research, Carmel CA
- 1993 "Epidemiology of Human Papillomavirus Infection in Women", MacFarlane Burnet Research Centre, Melbourne, Australia
- 1993 "Human Papillomavirus and Herpes Simplex Viral Infections" Workshop, Society for Adolescent Medicine, Los Angeles, CA
- 1994 "C. trachomatis and HPV: What's new in diagnosis & management", Advances and Controversies in Clinical Pediatrics, San Francisco
- 1994 "Risk Behavior in Adolescent Women", Symposium on Women's Health Issues, Reno, Nevada, January 1994
- 1995 "Women in Medicine", Society for Adolescent Medicine Annual Meeting, Vancouver, Canada, March 1995
- 1995 "Evaluation of Amenorrhea", AIDS in Adolescent" and HPV Infections," 6th Annual Conference in Adolescent Medicine sponsored by Symposia Medicus, Cozumel, Mexico, May 1995
- 1995 "Human Papillomavirus Infections," Association for Cytotechnologist, December 1995
- 1996 "Testicular Masses in Adolescents" and Update on Newer Contraceptives and Emergency Contraceptives," Ninth Annual Pediatrics in Yosemite, Valley Children's Hospital, March 1996
- 1997 "Natural History of HPV in Children and Adolescents," Grand Rounds, Department of Dermatology, University of California, San Francisco, March
- 1997 "Natural History of HPV Infection of the Cervix and Anus in Young Women," Seminar, Department of Epidemiology and Biostatistics, University of California, Berkeley
- 1997 "Human Papillomavirus Infections," Advances in STDs, San Francisco, STD/HIV Prevention Training Center, May
- 1997 "HIV Care of Children and Adolescents," Clinical care of the AIDS Patient, UCSF, San Francisco, December
- 1998 "Natural History of HPV," Grand Rounds, Department of Pediatrics, University of California, San Francisco, January
- 1998 "Pediatric and Adolescent HPV: Diagnosis and Management," American Society for Colposcopy and Cervical Pathology Biennial Meeting. Scottsdale, Arizona, March
- 1998 Panel Member, Health Care of Adolescent Women," American College of Physicians. 79<sup>th</sup> Annual Session. San Diego, March
- 1998 "HPV in adolescence," "HIV infection" and "Menstrual Disorders". 9<sup>th</sup> Annual Conference on Adolescent Medicine, Symposium Medicus. Cozumel, Mexico, May
- 1998 Human Papillomavirus Infection in Children and Adolescents. Pacific Dermatologic

- Association, 50<sup>th</sup> Annual Meeting, September
- 1999 “Human Papillomavirus Infection in Children and Adolescents: Myths and Speculations.” Grand Rounds, Department of Obstetrics and Gynecology, University of California, San Francisco.
- 2000 “Human Papillomavirus Infection in Adolescents,” Grand Rounds, Department of Pediatrics, University of California, San Francisco.
- 2000 “Understanding Cervical Cytology.” Society for Adolescent Medicine's Annual Meeting, Arlington, VA, March.
- 2000 “Anal HPV Infections in Adolescents with HIV.” Eurogin 2000: Global Challenge of Cervical Cancer Prevention, Paris, April.
- 2000 “HPV Infections in HIV Infected Adolescents,” Plenary Lecture, Fourth International AIDS Malignancy Conference, NCI, Bethesda, MD, May
- 2001 “Sexually Transmitted Infections in HIV Infected Adolescents,” Society for Adolescent Medicine, Workshop
- 2001 Children's Hospital of Oakland Advisory Group Meeting: *Faculty Development for General Pediatrics Generalist Faculty Teaching in Community Based Ambulatory Setting*, Health Resources and Services Administration (HRSA) and the Ambulatory Pediatric Association (APA)
- 2002 “HPV in HIV-infected Adolescents,” Plenary Lecture, Pediatrics AIDS Clinical Trials Group Annual Meeting; Crystal Springs, MD, May
- 2002 “Papillomavirus: New Guidelines in Pap Smear Screening,” Advances and Controversies in Clinical Pediatrics, San Francisco, CA, May
- 2002 “Controversies in HPV Management,” STI in the 21<sup>st</sup> Century, SFDPH/CDC, San Francisco, May
- 2002 “Natural History of HPV in Adolescents,” W.H.O., Lyon, France, October
- 2002 “Adolescents with HIV: Lessons Learned from REACH,” University of Florida, Jacksonville, FL, October
- 2002 “Natural History of HPV and Immunologic Responses,” Johns Hopkins Medical School, Baltimore, MD, November
- 2002 “HPV in HIV Infected Adolescents,” Women’s Health Committee Symposium, PACTG/ACTG Joint Meeting, Washington, DC, December
- 2003 “Update 2003: Pap smears in Teens.” Invited speaker for Society for Adolescent Medicine, Seattle Washington, March
- 2003 “Lessons Learned in HIV in Adolescents,” 11<sup>th</sup> Annual Improving the Management of HIV Disease, International AIDS Society, San Francisco, CA, March
- 2003 “Current Issues in STDs and Adolescents: Chlamydia, Genital Herpes and Human Papillomavirus infection,” Pediatric Academic Societies' Annual Meeting, Seattle, Washington, May
- 2003 “Epidemiology of Human Papillomavirus,” Epidemiology of Infectious Diseases, Stanford University, CA, May
- 2003 “Adolescents and Pap Smear Screening: Why and When,” Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, September
- 2003 “Adolescent Issues in Use of Microbicides,” Global Campaign, Ethical Issues in Clinical Trials of Vaginal Microbicides, Washington DC, October
- 2003 “When To Start Screening for Cervical Cancer,” Philadelphia Family Planning

- Council and Children's Hospital of Philadelphia, Philadelphia, November
- 2003 "Epidemiology and Natural history of HPV in HIV infected adolescents," Pediatric ACTG Symposium: HPV and HIV infected adolescents, Washington CD, December
- 2004 "New ASCCP and ACS Guidelines: Pap Smear Screening and Triage for Adolescents," Academy of Family Physicians: Infant Child and Adolescent Course, San Francisco, CA, November 16-21
- 2005 "Updates on new guidelines for Pap smear screening, triage and vaccine development," The 24th Annual Reproductive Health Update: Taking Care of Hawaii's Women, Honolulu, HI Feb 17-18
- 2005 "Pap Screening Guidelines: Ask The Expert," The 24<sup>th</sup> Annual Reproductive Health Update: Taking Care of Hawaii's Women, Honolulu, HI Feb 17-18
- 2005 "How Can We Prevent Cervical Cancer and Other HPV-related Diseases with Vaccine?" Society for Adolescent Medicine, Satellite Symposium, Los Angeles, CA, April 1<sup>st</sup>.
- 2005 "HPV and Cervical Cancers: What To Do With Screening, Follow-Up and Prevention In Adolescents and Young Women," Infant, Child and Adolescent Medicine, American Academy of Family Physicians, San Diego, CA, September 8<sup>th</sup>.
- 2005 "Human Papillomavirus Vaccines: Future Role of the Pediatrician in Preventing Cervical Cancer," Chair, Satellite Symposium, American Academy of Pediatrics, Washington DC, October 18th
- 2005 "HPV and Adolescents: update on new guidelines," University of Southern California, Grand Rounds, Division of Adolescent Medicine. October.
- 2006 "HPV Vaccines". American Academy of Dermatology, San Francisco, CA March,
- 2006 "Natural History Of Genital HPV and HPV Vaccines," American Academy of Dermatology 64<sup>th</sup> Annual Meeting, San Francisco, CA, March
- 2006 "Pathogenesis Of Human Papillomavirus (HPV) Infections," Pediatric Academic Societies Annual Meeting, San Francisco, CA, May
- 2006 "Human Papillomavirus and the Adolescent: What We Know and What We Can Do," North American Society for Pediatric and Adolescent Gynecology, 20th Annual Meeting; Alvin F Goldfarb Lectureship keynote speaker, Orlando, Florida, May.
- 2006 "Exploring the link between HPV and cervical cancer," California Family Health Council. San Francisco, CA October
- 2006 "Human Papillomavirus and the Adolescent: What We Know and What We Can Do," Children's Hospital Boston, Annual Robert P. Masland, Jr, Grand Rounds, Boston, MA, October 11-12.
- 2006 "Adolescent Pap Management and HPV Infection," Harvard Medical School, Pediatric and Adolescent Gynecology, Boston, MA, October 12-13.
- 2006 Pediatricians at the forefront of preventing cervical cancer: American Academy of Pediatrics; Satellite Symposium, Atlanta, GA, October.
- 2006 "Human Papillomavirus and the Adolescent: What We Know and What We Can Do," RUSH University, Cook County Grand Rounds, Chicago, IL October.
- 2007 "HPV: the beginning of the end." Western Society for Pediatric Research, State of the Art Lecture. Jan 31—Feb 3.
- 2007 "HPV-associated cancers and HIV: Will HPV vaccines make a difference?" CROI 2007: 14<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA February 28.

- 2007 “Does Failure Of Immune Response To HPV Lead To HPV-Induced Cancer?” AACR Annual Meeting 2007, Los Angeles, CA, April 14-18.
- 2007 “Genital HPV Infections: Is An End In Sight?” Women's & Pediatric Dermatology Seminar 2007, Skin Disease Education Foundation, San Francisco, CA, September 27-30.
- 2008 “Adolescents: Why Are They Different?” 2008 ASCCP Biennial Meeting, Orlando, FL, March 17-21.
- 2008 “Update on Cytology: Why Is Cytology Different?” The Sir John Dewhurst Lectureship, 2008 NASPAG Annual Clinical Meeting, Newport Beach, CA, April 16.
- 2009 “Approach to the adolescent with an STD.” American Academy of Dermatology, Winter Meeting, San Francisco, March 6-10, invited speaker.
- 2009 “Clinical Translation of HPV Research: Prevention, Policy and Therapeutics.” University of Hawaii, Grand Rounds Presentation, December 2.
- 2009 “Clinical Translation of Epidemiologic Studies of HPV in Adolescents: Why The End Of Paps In Adolescents.” University of California, San Diego, Ground Rounds Presentation, December 18.
- 2010 “Adolescents and Young Women: The Guidelines Applied and More – To Screen or NOT to Screen.” 2010 American Society for Colposcopy and Cervical Pathology Biennial Meeting, Las Vegas, March 24-27, 2010
- 2010 “HPV Prevention in Adolescents: It’s About Vaccinating, Not Screening” NASPAG 24th Annual Clinical Meeting, Issues and Answers in Pediatric and Adolescent Gynecology, Las Vegas, NV, April 15-17.
- 2010 “What We Do and Do Not Want to Know About HPV in Girls and Boys.” AAP Pediatric Controversies Conference, Sacramento, CA, December 4.
- 2011 “What We Do and Do Not Want to Know About HPV in Girls and Boys.” Marin General Hospital, Pediatric Grand Rounds, Greenbrae, CA, January 28.
- 2011 University of Arkansas for Medical Sciences (UAMS), Student’s Choice Speaker for Interdisciplinary Biomedical Sciences (IBS) Program, January.
- 2011 “HPV in Males.” HIV/AIDS on the Front Line, University of California, Irvine, CA, April 27
- 2011 “STI and HIV Research in Youth: Issues and Ethical Concerns.” Principles of STD and HIV Research, 19<sup>th</sup> Annual Summer Course, University of Washington, Seattle, WA, July 26.
- 2011 “HPV Vaccine Updates: Men and HIV.” Principles of STD and HIV Research, 19<sup>th</sup> Annual Summer Course, University of Washington, Seattle, WA, July 26.
- 2012 “Men and HPV.” 2012 ASCCP Biennial Scientific Meeting, San Francisco, CA, March 14-17.
- 2012 “Pro: Should Women be Screened for Anal Cancer?” 2012 ASCCP Biennial Scientific Meeting, San Francisco, CA, March 14-17.
- 2012 “Natural History of HPV Infection: Implications on Prevention and Management.” Louis Burke Lecture, Beth Israel Deaconess Medical Center, Boston, MA, August 22.
- 2012 “Why We Need to Vaccinate Boys and Men for HPV.” UCSF Dermatology Grand Rounds lecture, October 17.
- 2013 "Natural History of HPV and CIN in Adolescents: The Case of "Less" is Better." University of California, San Francisco, Department of Obstetrics, Gynecology & Reproductive Sciences, Grand Rounds lecture, May 14.



- 2013 “HPV in adolescent and young women: natural history and transmission: implications on prevention and management.” Autumn in NY Symposium, Albert Einstein College of Medicine, Montefiore Medical Center, New York, November 19.
- 2013 “HPV vaccine: Updates.” Autumn in NY Symposium, Albert Einstein College of Medicine, Montefiore Medical Center, New York, November 19.
- 2013 “Epidemiology of Anal HPV and AIN in Non-immunocompromised Men and Women.” International Anal Neoplasia Society; 1st Annual Meeting, San Francisco, Nov 22-24.
- 2014 “Human Papillomavirus Immune Responses and Vaccine Update: Real-Life Outcomes.” Seattle Children’s Hospital, Grand Rounds lecture, August 21.
- 2014 “Natural History of HPV in Women: Factors Influencing Clearance And Redetection.” HPV 2014 Seattle: 29th International Papillomavirus Conference & Clinical Workshop, Seattle, WA, August 20-25.
- 2014 "Screening and Surveillance For HPV-associated Anogenital Tract Disease in Women: What Do We Have to Offer?" American College of Surgeons Clinical Congress 2014 Annual Meeting, San Francisco, CA, October 27.
- 2014 "Human Papillomavirus Vaccine: Have We Conquered Cervical Cancer? Immune Responses and Real-life Outcomes" Current Topics in Pediatric and Adolescent Gynecology, North Shore University Hospital, Manhasset, New York, November 12.
- 2015 “Immune Response to HPV and HPV Vaccine Update” University of California, Los Angeles, David Geffen School of Medicine, Department of Obstetrics and Gynecology, Grand Rounds lecture, December 4.
- 2015 “Human papillomavirus: Transmission patterns and immune responses” University of California, Los Angeles, David Geffen School of Medicine, Department of Pediatrics, UCLA Children’s Discovery and Innovation Institute Seminar Series 2015-2016, December 17.
- 2016 “Does HPV Vaccine Induce Autoimmunity and Is It Safe for Women with Rheumatic Disease” 9<sup>th</sup> International Conference on Reproduction, Pregnancy and Rheumatic Diseases. San Diego, CA. March 31 – April 2.
- 2016 “Immune Response to HPV: Natural Infections and the Vaccine” UCLA Pediatrics Grand Rounds. Los Angeles, CA. May 27<sup>th</sup>
- 2017 “Immune Response to HPV: What Creates Protection” Winthrop P. Rockefeller Cancer Institute Grand Rounds. University of Arkansas Fayetteville, AR. April 26.
- 2017 “Natural history of HPV in Anogenital Cancers” 2017 Indian Health System Colposcopy Review. University of New Mexico School of Medicine. Albuquerque, NM. May 15<sup>th</sup>
- 2017 “Update on HPV Vaccines and immunization” 2017 Indian Health System Colposcopy Review. University of New Mexico School of Medicine. Albuquerque, NM. May 15<sup>th</sup>
- 2017 “HPV and HIV” 2017 Indian Health System Colposcopy Review. University of New Mexico School of Medicine. Albuquerque, NM. May 16<sup>th</sup>
- 2018 “Pre-Course Program: Management Guidelines” 2018 ASCCP Annual Meeting. Los Vegas, NV April 18<sup>th</sup>
- 2018 “Do Non-HIV Immunocomprised Patients Require Special Treatment?” 2018 ASCCP Annual Meeting. Los Vegas, NV April 19<sup>th</sup>
- 2018 “Should Screening Start at Age 25?” 2018 ASCCP Annual Meeting. Las Vegas, NV

- April 20<sup>th</sup>
- 2018 “Cervical Cytology: latest on cervical screening and management guidelines” National Reproductive Health Title X Conference, Kansas City, MO. July 15<sup>th</sup> - 18<sup>th</sup>
- 2019 “Warts and All: Prevention, Screening and Transmission of HPV” 2019 Contraceptive Technology West Conference. Anaheim, CA. March 24<sup>th</sup>-27<sup>th</sup>.
- 2019 “Challenging Cases in Colposcopy and Cervical Cancer Screening: Annual Scientific Meeting on Anogenital and HPV-related Disease; Pre-course Program”. ASCCP 2019 Annual Scientific Meeting on Anogenital and HPV related Disease, April 4.
- 2019 “Cervical Cancer screening in non-HIV immunosuppressed women” ASCCP 2019 Annual Scientific Meeting on Anogenital and HPV related Disease. Atlanta Ga. April 4-7.
- 2019 “Risk Modification Working Group for cervical cancer screening.” ASCCP 2019 Annual Scientific Meeting on Anogenital and HPV related Disease. Atlanta, GA. April 4-7.
- 2019 “Updates on Primary HPV vaccine prevention.” Olive View-UCLA Medical Center Grand Rounds. Los Angeles, CA. Nov 13<sup>th</sup>.
- 2020 “Natural History of HPV and Cervical Neoplasia.” Indian Health Review and Update on Colposcopy and HPV. Albuquerque, NM. Feb 18<sup>th</sup>.
- 2020 “Cervical cancer screening in women with immunosuppression.” Indian Health Review and Update on Colposcopy and HPV; School of Medicine University of New Mexico. Albuquerque, NM. Feb 18<sup>th</sup>.
- 2020 “The role of the vaginal microbiome in cervical cancer.” Indian Health Review and Update on Colposcopy and HPV. Albuquerque, NM. Feb 18<sup>th</sup>.
- 2020 “Everything your patient needs to know about HPV: Having those tough conversations with patients. HPV Transmission: Chicken or the Egg.” ASCCP Annual Scientific Meeting on Anogenital and HPV related Disease 2020, Virtual Presentation. Apr 1<sup>st</sup>.
- 2020 “Fundamental questions of the risk based management consensus guidelines. How were the clinical action thresholds developed and finalized: Risk Modifications.” ASCCP Annual Scientific Meeting on Anogenital and HPV related Disease 2020, Virtual Live Presentation. Apr 1<sup>st</sup>.
- 2021 American Cancer Society (ACS) Guidelines for Cervical Cancer Screening: The Changing Landscape for Clinicians and Patients; Society for Adolescent Health and Medicine: Virtual Chat Educational Series, April 28<sup>th</sup>.
- 2021 “Educating About Cervical Cancer Screening Amid the Pandemic: Update on Cervical Cancer Screening”, California Primary Care Association, live webinar presentation Apr 29, 2021
- 2021 “The Role of the Vaginal Microbiota in the Regression of hrHPV and CIN”. ASCCP Annual Scientific Meeting. Virtual Live Presentation, April 4-8, 2021
- 2021 ASCCP guidelines for management of abnormal cervical screening tests: Risk based management. Southern California Kaiser Permanente, virtual seminar series, December 16, 2021.

## **RESEARCH PAPERS**

### A. RESEARCH PAPERS – PEER REVIEWED

1. **Moscicki AB**, Shafer MA: Normal reproductive development in the adolescent female. *Journal of Adolescent Health Care*. 1986;7:41S-64S. PMID: 3536820.
2. Shafer MA, Vaughan E, Lipkin ES, **Moscicki AB**, Schachter J: Evaluation of the fluorescein-conjugated monoclonal antibody test (MicroTrak) to detect Chlamydia Trachomatis endocervical infections in adolescent girls. *Journal of Pediatrics*. 1986;108:779-783. PMID: 3517270.
3. **Moscicki AB**, Shafer MA, Millstein S, Irwin CE, Jr., Schachter J: Use and limitations of endocervical gram stains and mucopurulent cervicitis as predictors for C.trachomatis in adolescent females. *American Journal of Obstetrics and Gynecology*. 1987;157:65-71. PMID: 2440306.
4. Shafer MA, Prager V, Shalwitz J, Vaughan E, **Moscicki AB**, Brown R, Wibbelsman C, Schachter J. Prevalence of urethral Chlamydia Trachomatis and Neisseria Gonorrhoea among asymptomatic sexually active adolescent boys. *Journal of Infectious Diseases*. 1987;156:223-224. PMID: 3110306.
5. **Moscicki AB**, Winkler B, Irwin CE, Jr., Schachter J: Differences in biologic maturation, sexual behavior, and sexually transmitted disease between adolescents with and without cervical intra-epithelial neoplasia. *Journal of Pediatrics*. 1989;115:487-493. PMID: 2769512.
6. Shafer MA, Schachter J, **Moscicki AB**, Weiss A, Shalwitz J, Vaughan E, Millstein S: Urinary leukocyte esterase screening test for asymptomatic chlamydial and gonococcal infections in males. *JAMA* 1989;262:2562-2566. PMID: 2509742.
7. **Moscicki AB**, Palefsky J, Gonzales J, Schoolnik G: Human papillomavirus infection in sexually active adolescent females: prevalence and risk factors. *Pediatric Research*. 1990;28:507-513. PMID: 2175024.
8. **Moscicki AB**, Palefsky J, Gonzales J, Schoolnik G: The association between human papillomavirus deoxyribonucleic acid status and the results of cytology rescreening tests in young, sexually active women. *American Journal Obstetrics and Gynecology*. 1991;165:67-71. PMID: 1649551.
9. **Moscicki AB**, Palefsky J, Gonzales J, Schoolnik G: Colposcopic and histologic findings and human papillomavirus (HPV) DNA test variability in young positive women for HPV DNA. *Journal of Infectious Diseases*. 1992;166:951-957. PMID: 1328408.
10. Millstein S, **Moscicki AB**, Broering JM: Female adolescents at high, moderate and low risk of exposure to HIV: differences in knowledge, beliefs and behavior. *Journal of Adolescent Health*. 1993;15:133-142. PMID: 8018686.

11. **Moscicki AB:** Comparison between methods for human papillomavirus (HPV) DNA testing: a model for self-testing in young women. *Journal of Infectious Diseases*. 1993;167:723-725. PMID: 8382720.
12. **Moscicki AB,** Broering J, Powell K, Klein J, Clayton L, Smith G, Boero S, Darragh T, Brescia R, Palefsky J: Comparison between colposcopic, cytologic, and histologic findings in women positive and negative for human papillomavirus DNA. *Journal of Adolescent Health*. 1993;14:74-79. PMID: 8386548.
13. **Moscicki AB,** Millstein S, Broering J, Irwin CE, Jr.: Risks of human immunodeficiency virus infection among adolescents attending three diverse clinics. *Journal of Pediatrics*. 1993;122:813-820. PMID: 8496769.
14. **Moscicki AB,** Palefsky J, Smith G, Schoolnik G: Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. *Obstetrics and Gynecology*. 1993;82:578-585. PMID: 8397358.
15. Siadat-Pajouh M, Periasamy A, Lockett SJ, Ayscue AH, **Moscicki AB,** Palefsky JB, Herman B. Detection of human papillomavirus type 16/18 DNA in cervicovaginal cells by fluorescence based in situ hybridization and automated image cytometry. *Cytometry*. 1994;15:245-57. PMID: 8187584.
16. Millstein S, **Moscicki AB:** Sexually transmitted diseases in female adolescents: effects of psychosocial factors and high risk behaviors. *Journal of Adolescent Health*. 1995;17:83-90. PMID: 7495830.
17. **Moscicki AB,** Hunter S, Garland S, Quinn M, Crowe S, Shortman K, Stites D: A simple method for the propagation of cervical lymphocytes. *Clinical and Diagnostic Laboratory Immunology*. 1995;2:40-43. PMID: 771991. PMCID: PMC170098.
18. Nakagawa M, Stites DP, Farhat S, Judd A, **Moscicki AB,** Canchola AJ, Hilton JF, Palefsky JM: T cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. *Clinical and Diagnostic Laboratory Immunology*. 1996;3:205-210. PMID: 8991637. PMCID: PMC170279.
19. Nakagawa M, Stites DP, Farhat S, Sisler JJ, Moss AB, Kong F, **Moscicki AB,** Palefsky JM. Cytotoxic T Lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. *Journal of Infectious Diseases*. 1997;175:927-931. PMID: 9086151.
20. Ramirez JE, Ramos DB, Clayton L, Kanowitz S, **Moscicki AB:** Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women. *Journal of Women's Health*. 1997;6:113-121. PMID: 9065380.
21. **Moscicki AB,** Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller SB, Stone J, Hanson E, Palefsky J: The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young

- women. *Journal of Pediatrics*. 1998;132:277-84. PMID: 9506641.
22. Phillips SA, **Moscicki AB**, Kaufman M, Moore E. The composition of SAM: development of diversity. *Society for Adolescent Medicine. Journal of Adolescent Health*. 1998;23(6 Suppl):162-5. PMID: 9870304.
  23. Rogers AS, Futterman D, **Moscicki AB**, Wilson C, Ellenberg J, Vermund S: The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. *Journal of Adolescent Health*. 1998;22:300-311. PMID: 9561462.
  24. Douglas SD, Rudy B, Muenz L, **Moscicki AB**, Wilson C, Holland C, Crowley-Nowick P, Vermund SH, Adolescent Medicine HIV/AIDS Research Network: Peripheral blood mononuclear cell markers in antiretroviral therapy-naïve HIV-infected and high risk seronegative adolescents. *Adolescent Medicine HIV/AIDS Research Network. AIDS*. 13(13):1629-1635, 1999. PMID: 10509563.
  25. **Moscicki AB**, Grubbs Burt V, Kanowitz S, Darragh T, Shiboski S: The significance of squamous metaplasia in the development of low grade squamous intra-epithelial lesions in young women. *Cancer*. 1999, 85:1139-44. PMID: 10091799.
  26. **Moscicki AB**, Hills NK, Shiboski S, Darragh TM, Jay N, Powell K, Hanson E, Miller SB, Farhat S, Palefsky J: Risk factors for abnormal anal cytology in young heterosexual women. *Cancer Epidemiology, Biomarkers and Prevention*. 1999;8:173-178. PMID: 10067816.
  27. Nakagawa M, Stites D, Palefsky J, Kneass Z, **Moscicki AB**. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 response. *Clinical and Diagnostic Laboratory Immunology*. 1999;6(4):494-8. PMID: 10391849. PMCID: PMC95714.
  28. Scott M, Stites DP, **Moscicki AB**: Th1 cytokine patterns in cervical human papillomavirus infection. *Clinical and Diagnostic Laboratory Immunology*. 1999;6(5):751-5. PMID: 10473530. PMCID: PMC95767.
  29. Crowley-Nowick PA, Ellenberg JH, Vermund SH, Douglas SD, Holland CA, **Moscicki AB**: Cytokine profile in genital tract secretions from female adolescents: impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. *Journal of Infectious Diseases*. 2000;181(3):939-45. PMID: 10720516.
  30. Holland CA, Ellenberg JH, Wilson CM, Douglas SD, Futterman DC, Kingsley DC, **Moscicki AB**: Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescents. *AIDS Research and Human Retroviruses*. 2000;16(10):959-63. PMID: 10890357.
  31. Holland CA, Ma Y, **Moscicki AB**, Durako SJ, Levin L, Wilson CM: Seroprevalence and Risk Factors Of Hepatitis B, Hepatitis C, And Human Cytomegalovirus Among HIV-Infected and High-Risk Uninfected Adolescents: Findings of the Reaching for Excellence

- in Adolescent Care and Health Study (REACH). Sexually Transmitted Diseases. 2000;27(5):296-303. PMID: 10821605.
32. **Moscicki AB**, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-Nowick PA, Levin L, Wilson CW: Prevalence and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent women: Impact of infection with human immunodeficiency virus. Archives of Pediatrics and Adolescents. 2000;154(2):127-34. PMID: 10665598.
  33. Nakagawa M, Stites D, Patel S, Scott M, Hills N, Palefsky J, **Moscicki, AB**: Persistence of Human Papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. Journal of Infectious Diseases. 2000;182(2):595-8. PMID: 10915094.
  34. **Moscicki AB**, Ma Y, Holland C, Vermund SH. Cervical ectopy in adolescent girls with and without human immunodeficiency virus infection. Journal of Infectious Diseases. 2001;183(6):865-70. PMID: 11237802.
  35. **Moscicki AB**, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J: Risks for Incident Human Papillomavirus Infection and low-grade squamous intraepithelial lesion development young females. JAMA. 2001; 285(23):2995-3002. PMID: 11410098.
  36. Murphy DA, Durako SJ, **Moscicki AB**, Vermund SH, Ma Y, Schwarz DF, Muenz LR. No change in health risk behaviors over time among HIV infected adolescents in care: role of psychological distress. Journal of Adolescent Health. 2001;29(3 Suppl):57-63. PMID: 11530304.
  37. Schlecht NF, Franco EL, Rohan TE, Kjaer SK, Schiffman MH, **Moscicki AB**, Duffy SW. Repeatability of sexual history in longitudinal studies on HPV infection and cervical neoplasia: determinants of reporting error at follow-up interviews. Journal of Epidemiology and Biostatistics. 2001;6(5):393-407. PMID: 11822729.
  38. Shiboski CH, Wilson CM, Greenspan D, Hilton J, Greenspan JS, **Moscicki AB**: HIV-related oral manifestations among adolescents in a multicenter cohort study. Journal of Adolescent Health. 2001;29(3 Suppl):109-14. PMID: 11530311.
  39. Vermund SH, Wilson CM, Rogers AS, Partlow C, **Moscicki AB**. Sexually transmitted infections among HIV infected and HIV uninfected high-risk youth in the REACH study. Reaching for Excellence in Adolescent Care and Health. Journal of Adolescent Health. 2001;29(3 Suppl):49-56. PMID: 11530303.
  40. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, **Moscicki AB**. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clinical and Diagnostic Laboratory Immunology. 2002;9(4):877-82. PMID: 12093689.
  41. Nichter M, Nichter M, Thompson PJ, Shiffman S, **Moscicki AB**. Using qualitative research

- to inform survey development on nicotine dependence among adolescents. *Drug Alcohol Dependency*. 2002;68 Suppl 1:S41-56. PMID: 12324174.
42. Rudy BJ, Wilson CM, Durako S, **Moscicki AB**, Muenz L, Douglas SD. Peripheral blood lymphocyte subsets in adolescents: a longitudinal analysis from the REACH project. *Clinical and Diagnostic Laboratory Immunology*. 2002;9(5):959-65. PMID: 12204944. PMCID: PMC120048.
  43. Saslow D, Runowicz CD, Solomon D, **Moscicki AB**, Smith RA, Eyre HJ, Cohen C. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. *CA: A Cancer Journal for Clinicians*. 2002;52(6):342-62. PMID: 12469763.
  44. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, **Moscicki AB**, Fukumoto L. External genital warts: diagnosis, treatment, and prevention. *Clinical Infectious Diseases*. 2002;15;35(Suppl 2):S210-24. PMID: 12353208.
  45. Douglas SD, Camarca M, Xu J, Durako S, Murphy D, **Moscicki B**, Wilson C. The Relationships between Substance Abuse, Psychosocial Variables, and Natural Killer Cell Enumeration and Function in HIV-Infected and High-Risk Uninfected Adolescents. *AIDS Research and Human Retroviruses*. 2003; 19(5):399-408. PMID: 12803998.
  46. Douglas SD, Durako S, Sullivan KE, Camarca M, **Moscicki AB**, Wilson CM. TH1 and TH2 cytokine mRNA and protein levels in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative youths. *Clinical and Diagnostic Laboratory Immunology*. 2003;10(3):399-404. PMID: 12738638. PMCID: PMC154958.
  47. **Moscicki AB**, Durako SJ, Houser J, Ma Y, Murphy DA, Darragh TM, Farhat S, Wilson CM. Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents. *AIDS*. 2003;14;17(3):311-20. PMID: 12556684.
  48. **Moscicki AB**, Durako SJ, Yong M, Darragh T, Vermund SH. Utility of Cervicography in HIV-infected and uninfected adolescents. *Journal of Adolescent Health*. 2003;32:204-213. PMID: 12606114.
  49. Murphy DA, Sarr M, Durako SJ, **Moscicki AB**, Wilson CM, Muenz LR. Barriers to HAART Adherence Among HIV-Infected Adolescents. *Archives of Pediatrics and Adolescent Medicine*. 2003;157(3):249-255. PMID: 12622674.
  50. Straub DM, Hills NK, Thompson PJ, **Moscicki AB**: Effects of pro- and anti-tobacco advertising on non-smoking adolescents' intentions to smoke. *Journal of Adolescent Health*. 2003;32(1):36-43. PMID: 12507799.
  51. **Moscicki AB**, Ellenberg JH, Crowley-Nowick P, Darragh TM, Xu J, Farhat S. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. *Journal of Infectious Diseases*. 2004; 15;190(8):1413-21. PMID: 15378433.
  52. **Moscicki AB**, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences by

- phylogenetic types. *Journal of Infectious Diseases*. 2004;1;190(1):37-45. PMID: 15195241.
53. **Moscicki AB**, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura-Clayton KL, Farhat S, Broering JM, Darragh TM. Regression of low-grade squamous intra-epithelial lesions in young women. *Lancet*. 2004;6;364(9446):1678-83. PMID: 15530628.
  54. Nakagawa M, Kim KH, **Moscicki AB**. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. *Clinical and Diagnostic Laboratory Immunology*. 2004;11(5):889-96. PMID: 15358648. PMCID: PMC515262.
  55. Wilson CM, Ellenberg JH, Douglas SD, **Moscicki AB**, Holland CA; Reach Project Of The Adolescent Medicine HIV/AIDS Research Network. CD8+CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. *AIDS Research and Human Retroviruses*. 2004;20(5):575. PMID: 15117448.
  56. Nakagawa M, Kim KH, **Moscicki AB**. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. *Clinical and Diagnostic Laboratory Immunology*. 2005;12(8):1003-5. PMID: 16085919. PMCID: PMC1182184.
  57. Casper C, Meier AS, Wald A, Morrow RA, Corey L, **Moscicki AB**. Human herpesvirus 8 infection among adolescents in the REACH cohort. *Archives of Pediatrics and Adolescent Medicine*. 2006;160(9):937-42. PMID: 16953017.
  58. Frazer IH, Cox JT, Mayeaux EJ Jr, Franco EL, **Moscicki AB**, Palefsky JM, Ferris DG, Ferenczy AS, Villa LL. Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. *The Pediatric Infectious Disease Journal*. 2006;25(2 Suppl):S65-S81. PMID: 16462611.
  59. Harper DM, Franco EL, Wheeler CM, **Moscicki AB**, Romanowski B, Roteli-Martins CM, Jenkins D, Schuin A, Clemens SAC, Dubin G, HPV Vaccine Study Group. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. *Lancet*. 2006;15;367(9518):1247-55. PMID: 16631880.
  60. **Moscicki AB**, Ellenberg JH, Murphy DA, Jiahong X. Associations among body composition, androgen levels, and human immunodeficiency virus status in adolescents. *Journal of Adolescent Health*. 2006;39(2):164-73. PMID: 16857527.
  61. Scott ME, Ma Y, Farhat S, Shiboski S, **Moscicki AB**. Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of chlamydia trachomatis infection, hormonal contraception, and smoking. *Journal of Clinical Immunology*. 2006;26(3):222-32. PMID: 16783462.
  62. Smith-McCune KK, Tuveson JL, Rubin MM, Da Costa MM, Darragh TM, Shiboski SC, Van Der Pol B, **Moscicki AB**, Palefsky JM, Sawaya GF. Effect of Replens gel used with a



diaphragm on tests for human papillomavirus and other lower genital tract infections. *Journal of Lower Genital Tract Diseases*. 2006;10(4):213-8. PMID: 17012985.

63. Nakagawa M, Kim KH, Gillam TM, **Moscicki AB**. HLA Class I Binding Promiscuity of the CD8 T-Cell Epitopes of Human Papillomavirus Type 16 E6 Protein. *Journal of Virology*. 2007;81(3):1412-23. Epub 2006 Nov 15. PMID: 17108051. PMCID: PMC1797519.
64. Rubinstein ML, Thompson PJ, Benowitz NL, Shiffman S, **Moscicki AB**. Cotinine levels in relation to smoking behavior and addiction in young adolescent smokers. *Nicotine & Tobacco Research*. 2007;9(1):129-135. PMID: 17365743.
65. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, **Moscicki AB**, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE and Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. *CA: A Cancer Journal for Clinicians*. 2007;57(1):7-28. PMID: 17237032.
66. Diem K, Spitzer M, Twiggs LB, Cox JT, Kaufman RH, **Moscicki AB**, Rubin M. A 23-year-old woman has her first Pap smear, thin prep smear interpreted as "high grade squamous intraepithelial lesion". *Journal of Lower Genital Tract Disease*. 2008. 12: 54-58. PMID: 18162815.
67. Lieberman JA, **Moscicki AB**, Sumerel JL, Ma Y, Scott ME. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. *Clinical and Vaccine Immunology*. 2008;15: 49-54. PMID: 17978011. PMCID: PMC2223863.
68. Rubinstein ML, Benowitz NL, Auerback GM, **Moscicki AB**. A randomized trial of nicotine nasal spray in adolescent smokers. *Pediatrics*. 2008;122(3):e595-600. PMID: 18762494. PMCID: PMC2744418.
69. Rubinstein ML, Benowitz NL, Auerback GM, **Moscicki AB**. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. *Pediatrics*. 2008;122(3):e643-647. PMID: 18762498. PMCID: PMC2722964.
70. Wang X, **Moscicki AB**, Tsang L, Brockman A, Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. *Clinical and Vaccine Immunology*. 2008;15(6):937-45. PMID: 18448624. PMCID: PMC2446617.
71. **Moscicki AB**, Smith JS. Issues in human papillomavirus vaccination in adolescents. *Journal of Adolescent Health*. 2008;43(4 Suppl):S1-4. PMID: 18809142.
72. Sawaya GF, Chirenje MZ, Magure MT, Tuveson JL, Ma Y, Shiboski SC, Da Costa MM, Palefsky JM, **Moscicki AB**, Mutasa RM, Chipato T, Smith-McCune KK. Effect of diaphragm and lubricant gel provision on human papillomavirus infection among women

provided with condoms: a randomized controlled trial. *Obstetrics and Gynecology*. 2008;112(5):990-997. PMID: 18978097.

73. **Moscicki AB**, Ma Y, Wibbelsman C, Powers A, Darragh TM, Farhat S, Shaber R, Shiboski S. Risks for Cervical Intraepithelial Neoplasia 3 Among Adolescents and Young Women With Abnormal Cytology. *Obstetrics and Gynecology*. 2008;112(6):1335-1342. PMID: 19037044. PMCID: PMC2735396.
74. Farhat S, Nakagawa M, **Moscicki AB**. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. *International Journal of Gynecological Cancer*. 2009;19:508-12. PMID: 19509544. PMCID: PMC2766534.
75. Fukuchi E, Sawaya GF, Chirenje M, Magure T, Tuveson J, Ma Y, Shiboski S, Da Costa M, Palefsky J, **Moscicki AB**, Makunike-Mutasa R, Chipato T, Smith-McCune KK. Cervical human papillomavirus incidence and persistence in a cohort of HIV-negative women in Zimbabwe. *Sexually Transmitted Diseases*. 2009;36(5):305-311. PMID: 19295468.
76. Hwang LY, Ma Y, Benningfield SM, Clayton L, Hanson EN, Jay J, Jonte J, Godwin de Medina C, **Moscicki AB**. Factors that influence the rate of epithelial maturation in the cervix in healthy young women. *Journal of Adolescent Health*. 2009;44(2):103-110. PMID: 19167657. PMCID: PMC2662755.
77. Rubinstein ML, Benowitz NL, Auerback GM, **Moscicki AB**. Withdrawal in adolescent light smokers following 24-hour abstinence. *Nicotine & Tobacco Research*. 2009;11(2):185-189. PMID: 19246428. PMCID: PMC2658900.
78. Scott ME, Ma Y, Kuzmich L, **Moscicki AB**. Diminished IFN- $\gamma$  and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. *International Journal of Cancer*. 2009;124:1379-83. PMID: 19089920. PMCID: PMC2696072.
79. The GlaxoSmithKilinc Vaccine HPV-007 Study Group: Romanowski B, de Borja PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, **Moscicki AB**, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. *Lancet*. 2009;374:1975-85. PMID: 19962185.
80. **Moscicki AB**, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. *Journal of Lower Genital Tract Disease*. 2010;14:73-80. PMID: 20043357. PMCID: PMC3058950.
81. Barnes W, D'Angelo L, Yamazaki M, Belzer M, Schroeder S, Palmer-Castor J, Futterman D, Kapogiannis B, Muenz L, Harris DR, Ellen JM. Identification of HIV-infected 12- to

- 24-year-old men and women in 15 US cities through venue-based testing. *Archives of Pediatrics & Adolescent Medicine*. 2010;164(3):273-276. PMID: 20194262. PMCID: PMC2903430. (Site Investigator)
82. Smith-McCune KK, Shiboski S, Chirenje MZ, Magure T, Tuveson J, Ma Y, Da Costa M, **Moscicki AB**, Palefsky JM, Makunike-Mutasa R, Chipato T, van der Straten A, Sawaya GF. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. *PLoS One*. 2010;5(4):e10094. PMID: 20386706. PMCID: PMC2851652.
  83. Widdice LE, Breland DJ, Jonte J, Farhat S, Ma Y, Leonard AC, **Moscicki AB**. Human Papillomavirus (HPV) concordance in heterosexual couples. *Journal of Adolescent Health*. 2010;47(2):151-9. PMID: 20638007. PMCID: PMC2967294.
  84. **Moscicki AB**, Ma Y, Jonte J, Miller-Benningfield S, Hanson L, Jay J, Godwin de Medina C, Farhat S, Clayton L, Shiboski S. The role of sexual behavior and HPV persistence in predicting repeated infections with new HPV types. *Cancer Epidemiology Biomarkers and Prevention*. 2010;19(8):2055-65. PMID: 20696663. PMCID: PMC292057.
  85. Cohen CR, **Moscicki AB**, Scott ME, Ma Y, Shiboski S, Bukusi E, Daud I, Rebbapragada A, Brown J, Kaul R. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. *AIDS*. 2010;24(13):2069-74. PMID: 20588163. PMCID: PMC2914808.
  86. Levin MJ, **Moscicki AB**, Song L-Y, Fenton T, Meyer WA, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A, IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Vaccine in HIV-Infected Children 7 to 12 Years Old. *Journal of AIDS*. 2010; 55(2):197-204. PMID: 205774412. PMCID: PMC3033215.
  87. **Moscicki AB**, Widdice L, Ma Y, Farhat S, Miller-Benningfield, S, Jonte J, Jay J, Godwin-deMedina C, Hanson E, Clay L, Shiboski S. Comparison of natural histories of Human Papillomavirus (HPV) detected by clinician- and self- sampling. *International Journal of Cancer*. 2010;127(8):1882-92. PMID: 20104517. PMCID: PMC3132413.
  88. **Moscicki AB**, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S. Rate of and risks for regression of CIN-2 in adolescents and young women. *Obstetrics and Gynecology*. 2010;116(6):1373-80. PMID: 21099605. PMCID: PMC3057366.
  89. Hwang LY, Scott M, Ma Y, **Moscicki AB**. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. *Journal of Reproductive Immunology*. 2011; 88:66-71. PMID: 21051089. PMCID: PMC3049722.
  90. Rubinstein ML, Luks TL, **Moscicki AB**, Dryden W, Rait MA, Simpson GV. Smoking-related cue-induced brain activation in adolescent light smokers. *Journal of Adolescent Health*. 2011;48(1):7-12. PMID: 21185518. PMCID: PMC3058837.

91. Diouf K, Sawaya GF, Shiboski S, Magure T, Makunike-Mutasa R, Darragh TM, Tuveson J, Chipato T, Palefsky JM, **Moscicki AB**, Chirenje M, Smith-McCune K. Investigating potential associations between cervical procedures and HIV acquisition. *ISRN Obstetrics and Gynecology*. 2011;789106. PMID: 22191049. PMCID: PMC3236408.
92. Cohen CR, Brown J, **Moscicki AB**, Bukusi EA, Paull JR, Price CF, Shiboski S. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. *PLoS One*. 2011;6(1):e16258. PMID: 21311578. PMCID: PMC3024437.
93. Daud, II, Scott ME, Ma Y, Shiboski S, Farhat S, **Moscicki AB**. Association between toll-like receptors expression and human papillomavirus type 16 persistence. *International Journal of Cancer*. 2011;128(4):879-86. PMID: 20473890. PMCID: PMC2952342.
94. Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, Giovannelli L, Coutlee F, Hibbitts S, Chu TY, Settheetham-Ishida W, Picconi MA, Ferrera A, De Marco F, Woo YL, Raiol T, Pina-Sanchez P, Cheung JL, Bae JH, Chirenje MZ, Magure T, **Moscicki AB**, Fiander AN, Di Stefano R, Cheung TH, Yu MM, Tsui SK, Pim D, Banks L. Identification of human papillomavirus type 58 lineages and the distribution worldwide. *Journal of Infectious Diseases*. 2011;203:1565-1573. PMID: 21592985.
95. Mellins CA, Tassiopoulos K, Malee K, **Moscicki AB**, Patton D, Smith R, Usitalo A, Allison SM, Van Dyke R, Seage GR, 3rd. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. *AIDS Patient Care STDS*. 2011;25(7):413-422. PMID: 21992620. PMCID: PMC3125549.
96. Straub DM, Arrington-Sanders R, Harris DR, Willard N, Kapogiannis B, Emmanuel P, Futterman D, Ellen JM. Correlates of HIV testing history among urban youth recruited through venue-based testing in 15 US cities. *Sexually Transmitted Diseases*. 2011;38(8):691-696. PMID: 21758020. PMCID: PMC3155007. (Site investigator)
97. Freeman P, Walker BC, Harris DR, Garofalo R, Willard N, Ellen JM. Methamphetamine use and risk for HIV among young men who have sex with men in 8 US cities. *Archives of Pediatrics & Adolescent Medicine*. 2011;165(8):736-740. PMID: 21810635. PMCID: PMC3278965. (Site Investigator)
98. Scott ME, Wilson SS, Cosentino LA, Richardson BA, **Moscicki AB**, Hillier SL, Herold BC. Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: Implications for microbicide safety studies. *Cytokine*. 2011;56(2):430-434. PMID: 21764598. PMCID: PMC3185204.
99. Hemmerling A, Harrison WG, Brown JM, **Moscicki B**, Oziemkowska M, Bukusi EA, Cohen CR. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. *Sexually Transmitted Diseases*. 2012;39(9):710-712. PMID: 22902667. PMCID: PMC3726043.
100. Garber AK, Michihata N, Hetnal K, Shafer M-A & **Moscicki A-B**. A Prospective

examination of weight gain in hospitalized adolescents with anorexia nervosa on a recommended refeeding protocol. *Journal of Adolescent Health*. 2012;50(1):24-29. PMID: 22188830. PMCID: PMC4467563.

101. Coleman H, **Moscicki AB**, Farhat S, Gupta S, Wang X, Nakagawa M. CD8 T-Cell Responses in incident and prevalent Human Papillomavirus types 16 and 18 infections. *ISRN Obstetrics and Gynecology*. 2012;2012:1-4. PMID: 22523697. PMCID: PMC3316950.
102. **Moscicki AB**, Kaul R, Ma Y, Scott ME, Daud, II, Bukusi EA, Shiboski S, Rebbapragada A, Huibner S, Cohen CR. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. *Journal of Acquired Immune Deficiency Syndrome*. 2012;59(2):134-140. PMID: 22067666. PMCID: PMC3261360.
103. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Jr., Spitzer M, **Moscicki AB**, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *American Journal of Clinical Pathology*. 2012;137(4):516-542. PMID: 22431528.
104. Hwang LY, Lieberman JA, Ma Y, Farhat S, **Moscicki AB**. Cervical ectopy and the acquisition of human papillomavirus in adolescents and young women. *Obstetrics & Gynecology*. 2012;119(6):1164-70. PMID: 22617581. PMCID: PMC3694771.
105. Hwang LY, Ma Y, Shiboski SC, Farhat S, Jonte J, **Moscicki AB**. Active squamous metaplasia of the cervical epithelium is associated with subsequent acquisition of human papillomavirus 16 infection among healthy young women. *Journal of Infectious Diseases*. 2012;206(4):504-511. PMID: 22696500. PMCID: PMC3491738.
106. Weinberg A, Song LY, Saah A, Brown M, **Moscicki AB**, Meyer III WA, Bryan J, Levin MJ for the IMPAACT/PACTG P1047 team. Humoral, mucosal and cell-mediated immunity against vaccine and non-vaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. *Journal of Infectious Diseases*. 2012; 206(8):1309-1318. PMID: 22859825. PMCID: PMC3529604.
107. Denny LA, Franceschi S, de Sanjose S, Heard I, **Moscicki AB**, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. *Vaccine*. 2012;30 Suppl 5:F168-174. PMID: 23199960.
108. **Moscicki AB**, Schiffman M, Burchell A, Albero G, Giuliano A, Goodman MT, Kjaer SK, Palefsky J. Updating the natural history of HPV and anogenital cancers. *Vaccine*. 2012;30 Suppl 5:F24-33. PMID: 23199964. PMCID: PMC3700362.
109. Waxman AG, Chelmow D, Darragh TM, Lawson H, **Moscicki AB**. Revised terminology for cervical histopathology and its implications for management of high-grade squamous

- intraepithelial lesions of the cervix. *Obstetrics and Gynecology*. 2012;120(6):1465-1471. PMID: 23168774. PMCID: PMC4054813.
110. **Moscicki AB**, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, Descamps D, Schuind A. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. *Vaccine*. 2012;31(1):234-241. PMID: 23063422.
  111. Tassiopoulos K, **Moscicki AB**, Mellins C, Kacanek D, Malee K, Allison S, Hazra R, Siberry GK, Smith R, Paul M, Van Dyke RB, Seage GR, 3rd. Sexual Risk Behavior Among Youth With Perinatal HIV Infection in the United States: Predictors and implications for intervention development. *clinical infectious diseases*. 2013;56(2):283-290. PMID: 23139252. PMCID: PMC3526253.
  112. Rubinstein ML, Shiffman S, **Moscicki AB**, Rait MA, Sen S, Benowitz NL. Nicotine metabolism and addiction among adolescent smokers. *Addiction*. 2013;108(2):406-412. PMID: 22823143. PMCID: PMC3504133.
  113. Widdice L, Ma Y, Jonte J, Farhat S, Breland D, Shiboski S, **Moscicki AB**. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. *Journal of Infectious Diseases*. 2013;207(8):1286-94. PMID: 23319742. PMCID: PMC3603534.
  114. Chan PK, Zhang C, Park JS, Smith-McCune KK, Palefsky JM, Giovannelli L, Coutlee F, Hibbitts S, Konno R, Settheetham-Ishida W, Chu TY, Ferrera A, Alejandra Picconi M, De Marco F, Woo YL, Raiol T, Pina-Sanchez P, Bae JH, Wong MC, Chirenje MZ, Magure T, **Moscicki AB**, Fiander AN, Capra G, Young Ki E, Tan Y, Chen Z, Burk RD, Chan MC, Cheung TH, Pim D, Banks L. Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. *International Journal of Cancer*. 2013; 132 (11) :2528-2536. PMID: 23136059. PMCID: PMC3962828.
  115. **Moscicki AB**, Ma Y, Farhat S, Darragh TM, Pawlita M, Galloway DA, Shiboski S. Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16. *Journal of Infectious Diseases*. 2013;208(3):403-412. PMID: 235999313. PMCID: PMC3699002.
  116. Scott ME, Shvetsov YB, Thompson PJ, Hernandez BY, Zhu X, Wilkens LR, Killeen J, Vo D, **Moscicki AB**, Goodman MT. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. *International Journal of Cancer*. 2013; 133(5):1187-96. PMID: 23436563. PMCID: PMC3732505.
  117. Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. *The Pediatric Infectious Disease Journal*. 2013;32 Suppl 2:i-KK4. PMID: 24569199. PMCID: PMC4169043.

(**Moscicki** author HPV chapter)

118. Bosch FX, Broker TR, Forman D, **Moscicki AB**, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsague X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, Sanjose S. Comprehensive control of human papillomavirus infections and related diseases. *Vaccine*.2013;31 Suppl 8:I1-I31. PMID: 24229716. PMCID: PMC4062073.
119. Garber AK, Mauldin K, Michihata N, Buckelew SM, Shafer MA, **Moscicki AB**. Higher calorie diets increase rate of weight gain and shorten hospital stay in hospitalized adolescents with anorexia nervosa. *Journal of Adolescent Health*.2013;53(5):579-584. PMID: 24054812. PMCID: PMC4452504.
120. Siberry GK, Abzug MJ, Nachman S. Executive summary: 2013 update of the guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. *The Pediatric Infectious Disease Journal*. 2013;32(12):1303-1307. PMID: 24569304. PMCID: PMC3937852. (**Moscicki** author HPV chapter)
121. **Moscicki AB**, Puga A, Farhat S, Ma Y. Human papillomavirus infections in nonsexually active perinatally HIV infected children. *AIDS Patient Care and STDS*. 2014;28(2):66-70. PMID: 24460009. PMCID: PMC3926149.
122. Alperen J, Brummel S, Tassiopoulos K, Mellins CA, Kacanek D, Smith R, Seage GR, 3rd, **Moscicki AB**. Prevalence of and risk factors for substance use among perinatally human immunodeficiency virus-infected and perinatally exposed but uninfected youth. *Journal of Adolescent Health*. 2014;54(3)341-349. PMID: 24239286. PMCID: PMC3944021.
123. **Moscicki AB**, Ma Y, Farhat S, Jay J, Hanson E, Benningfield S, Jonte J, Godwin-Medina C, Wilson R, Shiboski S. Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence. *Clinical Infectious Diseases* 2014;58(6):804-11. PMID: 24368624. PMCID: PMC3935503.
124. Hwang LY, Ma Y, **Moscicki AB**. Biological and behavioral risks for incident Chlamydia trachomatis infection in a prospective cohort. *Obstetrics and gynecology*. 2014;124(5):954-960. PMID: 25437724. PMCID: PMC4251549.
125. Zhang C, Park JS, Grce M, Hibbitts S, Palefsky JM, Konno R, Smith-McCune KK, Giovannelli L, Chu TY, Picconi MA, Pina-Sanchez P, Settheetham-Ishida W, Coutlee F, De Marco F, Woo YL, Ho WC, Wong MC, Chirenje MZ, Magure T, **Moscicki AB**, Sabol I, Fiander AN, Chen Z, Chan MC, Cheung TH, Burk RD, Chan PK. Geographical distribution and risk association of human papillomavirus genotype 52-variant lineages. *Journal of Infectious Diseases*. 2014;210(10):1600-04. PMID: 24879800. PMCID: PMC4539913.
126. Farhat S, Scott ME, Ma Y, **Moscicki AB**. Development of a novel liquid bead array human papillomavirus genotyping assay (PGMY-LX) and comparison with linear array for continuity in longitudinal cohort studies. *Journal of clinical microbiology*.

2015;53(4):1270-1276. PMID: 25653406. PMCID: PMC4365227.

127. Scott ME, Ma Y, Farhat S, **Moscicki AB**. Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response. *International Journal of Cancer*. 2015;136(10):2402-8. PMID: 25346143. PMCID: PMC4355215.
128. Hwang LY, Scott ME, Ma Y, **Moscicki AB**. Diversity of Cervicovaginal Cytokine Response to Incident Chlamydia trachomatis Infection Among a Prospective Cohort of Young Women. *American Journal of Reproductive Immunology*. 2015;74(3):228-36. PMID: 25989718. PMCID: PMC4564257
129. **Moscicki AB**, Darragh TM, Berry-Lawhorn JM, Roberts JM, Khan MJ, Boardman LA, Chiao E, Einstein MH, Goldstone SE, Jay N, Likes WM, Stier EA, Welton ML, Wiley DJ, Palefsky JM. Screening for Anal Cancer in Women. *Journal of Lower Genital Tract Disease*. 2015;19(3):S27-42. PMID: 26103446. PMCID: PMC4479419.
130. Garland SM, Subasinghe AK, Jayasinghe YL, Wark JD, **Moscicki AB**, Singer A, Bosch X, Cusack K, Stanley M. HPV vaccination for victims of childhood sexual abuse. *Lancet*. 2015; 386(10007):1919-20. PMID:26841735. PMCID – In Process.
131. Speicher DJ, Ramirez-Amador V, Dittmer DP, Webster-Cyriaque J, Goodman MT, **Moscicki AB**. Viral infections associated with oral cancers and diseases in the context of HIV: a workshop report. *Oral Dis*. 2016;22(S1):181-92. PMID:27109286. PMCID: PMC5590239
132. **Moscicki AB**, Yao, TJ, Rider MI, Russel JR, Dominy SS, Patel K, McKenna M, Van Dyke RB, Seage GR, Hazar R, Shiboski C. The Burden of oral disease among perinatally HIV-infected and HIV-exposed uninfected youth. *PLOS One*. 2016 Jun 14;11(6):e0156459. PMID: 27299992. PMCID: PMC4907464
133. **Moscicki AB**, Farhat S, Yao TJ, Rider MI, Russell JS, Van Dyke RB, Hazra R, Shiboski C. Oral human papillomavirus in youth from the pediatric HIV/AIDS cohort study. *Sex Transm Dis*. 2016 Aug;43(8):498-500. PMID: 27414680. PMCID:PMC4956007
134. Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, Blatter M, **Moscicki AB**, Harper DM, Romanowski B, Tyring SK, Ramjattan B, Schuind A, Dubin G, Franco EL; HPV-007 Study Group. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. *BMJ Open*. 2016 Aug 26;6(8):. PMID: 27566633 PMCID: PMC5013348
135. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, Rivera B, Ramírez P, Mendiola-Pastrana I, Rudolph SE, León-Maldonado L, Hernández R, Barrios E, Gravitt P, **Moscicki AB**, Schmeler KM, Flores YN, Méndez-Hernández P, Salmerón J; FRIDA Study Group. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA study. *Salud Publica Mex*. 2016 Apr;58(2):197-210. PMID: 27557378



136. Kyrgiou M, Mitra A, **Moscicki AB**. Does the vaginal microbiota play a role in the development of cervical cancer? *Transl Res*. 2017 Jan;179:168-182. doi: 10.1016/j.trsl.2016.07.004. Epub 2016 Jul 15. Review. PubMed PMID: 27477083; PubMed Central PMCID: PMC5164950.
137. Levin MJ, Huang S, **Moscicki AB**, Song LY, Read JS, Meyer WA, Saah AJ, Richardson K, Weinberg A; IMPAACT P1085 Protocol Team. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. *Vaccine*. 2017 Mar 23;35(13):1712-1720. doi: 10.1016/j.vaccine.2017.02.021. Epub 2017 Feb 24.
138. **Moscicki AB**, Ma Y, Gheit T, McKay-Chopin S, Farhat S, Widdice LE, Tommasino M. prevalence and transmission of beta and gamma human papillomavirus in heterosexual couples. *Open Forum Infect Dis*. 2017 Jan 31;4(1):ofw216. doi: 10.1093/ofid/ofw216. eCollection 2017 Winter. PubMed PMID: 28480229; PubMed Central PMCID: PMC5414092.
139. Averbach SH, Ma Y, Smith-McCune K, Shiboski S, **Moscicki AB**. The effect of intrauterine devices on acquisition and clearance of human papillomavirus. *Am J Obstet Gynecol*. 2017 Apr;216(4):386.e1-386.e5. doi: 10.1016/j.ajog.2016.11.1053. Epub 2016 Dec 14. PubMed PMID: 27986460; PubMed Central PMCID: PMC5406303.
140. Wentzensen N1, Massad LS, Mayeaux EJ Jr, Khan MJ, Waxman AG, Einstein MH, Conageski C, Schiffman MH, Gold MA, Apgar BS, Chelmow D, Choma KK, Darragh TM, Gage JC, Garcia FAR, Guido RS, Jeronimo JA, Liu A, Mathews CA, Mitchell MM, **Moscicki AB**, Novetsky AP, Papasozomenos T, Perkins RB, Silver MI, Smith KM, Stier EA, Tedeschi CA, Werner CL, Huh WK. Evidence-based consensus recommendations for colposcopy practice for cervical cancer prevention in the United States. *J Low Genit Tract Dis*. 2017 Oct;21(4):216-222. doi: 10.1097/LGT.0000000000000322. PMID: 28953109
141. Khan MJ, Werner CL, Darragh TM, Guido RS, Mathews C, **Moscicki AB**, Mitchell MM, Schiffman M, Wentzensen N, Massad LS, Mayeaux EJ Jr, Waxman AG, Conageski C, Einstein MH, Huh WK. ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, potential harms, and terminology for colposcopic practice. *J Low Genit Tract Dis*. 2017 Oct;21(4):223-229. doi: 10.1097/LGT.0000000000000338. PMID: 28953110.
142. Garland SM, Brotherton JML, **Moscicki AB**, Kaufmann AM, Stanley M, Bhatla N, Sankaranarayanan R, de Sanjosé S, Palefsky JM; IPVS. HPV vaccination of immunocompromised hosts. *Papillomavirus Res*. 2017 Dec;4:35-38. doi: 10.1016/j.pvr.2017.06.002. Epub 2017 Jun 3. PMID: 29179867. PMCID: PMC5883202.
143. Garland SM, Giuliano A, Brotherton J, **Moscicki AB**, Stanley M, Kaufmann AM, Bhatla N, Sankaranarayanan R, Palefsky JM, de Sanjose S; IPVS. IPVS statement moving towards elimination of cervical cancer as a public health problem. *Papillomavirus Res*. 2018 Feb 27;5:87-88. doi: 10.1016/j.pvr.2018.02.003. PMID: 29499389. PMCID: PMC5887016.
144. Weinberg A, Huang S, **Moscicki AB**, Saah A, Levin MJ; IMPAACT P1085 Protocol

- Team. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. *AIDS*. 2018 Apr 24;32(7):851-860. doi: 10.1097/QAD.0000000000001773. PMID: 29424778. PMCID: PMC5869173.
145. Thiel de Bocanegra H, Navarro SK, Nonzee NJ, Vangala S, Zhou X, Chang C, **Moscicki AB**. Trends in Cervical Cancer Screening in California's Family Planning Program. *J Low Genit Tract Dis*. 2018 Jul;22(3):171-177. doi: 10.1097/LGT.0000000000000376. PMID: 29474237. PMCID: PMC6014881.
  146. Garland SM, Giuliano A, Brotherton J, **Moscicki AB**, Stanley M, Kaufmann AM, Bhatla N, Sankaranarayanan R, Palefsky JM, de Sanjose S; IPVS. IPVS statement moving towards elimination of cervical cancer as a public health problem. *Papillomavirus Res*. 2018 Jun;5:87-88. doi: 10.1016/j.pvr.2018.02.003. Epub 2018 Feb 27. PMID: 29499389. PMCID: PMC5887016.
  147. Starr JR, Huang Y, Lee KH, Murphy CM, **Moscicki AB**, Shiboski CH, Ryder MI, Yao TJ, Faller LL, Van Dyke RB, Paster BJ; Pediatric HIV/AIDS Cohort Study. Oral microbiota in youth with perinatally acquired HIV infection. *Microbiome*. 2018 May 31;6(1):100. doi: 10.1186/s40168-018-0484-6. PMID: 29855347. PMCID: PMC5984365.
  148. **Moscicki AB**, Perkins RB, Saville M, Brotherton JML. Should cervical cancer screening be performed before the age of 25 years? *J Low Genit Tract Dis*. 2018 Aug 30. doi: 10.1097/LGT.0000000000000434. PMID: 30169418. PMCID: PMC6250286.
  149. Halec G, Scott ME, Farhat S, Darragh TM, **Moscicki AB**. Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2. *Int J Cancer*. 2018 Aug 19. doi: 10.1002/ijc.31814. PMID:30121951. PMCID: PMC6419742.
  150. Shiboski CH, Yao TJ, Russell JS, Ryder MI, Van Dyke RB, Seage GR 3rd, **Moscicki AB**; Pediatric HIV/AIDS Cohort Study. The association between oral disease and type of antiretroviral therapy among perinatally HIV-Infected youth. *AIDS*. 2018 Aug 8. doi: 10.1097/QAD.0000000000001965. PMID: 30096069. PMCID: PMC6494108.
  151. Lee KH, Coull BA, **Moscicki AB**, Paster BJ, Starr JR. Bayesian variable selection for multivariate zero-inflated models: Application to microbiome count data. *Biostatistics*. 2018 Dec. 26. doi:10.1093/biostatistics/kxy067. PMID: 30590511. PMCID: PMC7308073.
  152. Lin C, Slama J, Gonzalez P, Goodman MT, Xia N, Kreimer AR, Wu T, Hessol NA, Shvetsov Y, Ortiz AP, Grinsztejn B, **Moscicki AB**, Heard I, Del Refugio González Losa M, Kojic EM, Schim van der Loeff MF, Wei F, Longatto-Filho A, Mbulawa ZA, Palefsky JM, Sohn AH, Hernandez BY, Robison K, Simpson S Jr, Conley LJ, de Pokomandy A, van der Sande MAB, Dube Mandishora RS, Volpini LPB, Pierangeli A, Romero B, Wilkin T, Franceschi S, Hidalgo-Tenorio C, Ramautarsing RA, Park IU, Tso FK, Godbole S, D'Hauwers KWM, Sehna B, Menezes LJ, Heráclio SA, Clifford GM. Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. *Lancet Infectious Disease*. 2019 Jun 13. pii: S1473-3099(19)30164-1. doi: 10.1016/S1473-3099(19)30164-1. PMID: 3124304. PMCID: PMC6656696.

153. Zeng Y, **Moscicki AB**, Sahasrabuddhe VV, Garcia F, Woo H, Hsu CH, Szabo E, Dimond E, Vanzzini S, Mondragon A, Butler V, DeRose H, Chow HS. A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol. *BMC Cancer*. 2019 Apr 1;19(1):290. doi: 10.1186/s12885-019-5444-4. PMID: 30935375; PMCID: PMC6444524.
154. **Moscicki AB**, Karalius B, Tassiopoulos K, Yao TJ, Jacobson DL, Patel K, Purswani M, Seage GR; Pediatric HIV/AIDS Cohort Study. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth. *Clin Infect Dis*. 2019 Feb 21. pii: ciy1040. doi: 10.1093/cid/ciy1040. [Epub ahead of print]. PMID: 30927547.
155. **Moscicki AB**, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, Spiryda LB, Gold MA. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. *J Low Genit Tract Dis*. 2019 Apr; 23(2): 87-101. doi: 10.1097/LGT.0000000000000468. PMID: 30907775.
156. El-Zein M, Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, Colares de Borba P, Teixeira JC, **Moscicki AB**, Harper DM, Tyring SK, Ramjattan B, Dubin G, Franco EL; HPV-007 Study Group. Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. *Sex Transm Dis*. 2019 Oct;46(10):663-669. doi: 10.1097/OLQ.0000000000001053. PMID: 31464859; PMCID: PMC6887628.
157. Lin C, Slama J, Gonzalez P, Goodman MT, Xia N, Kreimer AR, Wu T, Hessol NA, Shvetsov Y, Ortiz AP, Grinsztejn B, **Moscicki AB**, Heard I, Del Refugio González Losa M, Kojic EM, Schim van der Loeff MF, Wei F, Longatto-Filho A, Mbulawa ZA, Palefsky JM, Sohn AH, Hernandez BY, Robison K, Simpson S Jr, Conley LJ, de Pokomandy A, van der Sande MAB, Dube Mandishora RS, Volpini LPB, Pierangeli A, Romero B, Wilkin T, Franceschi S, Hidalgo-Tenorio C, Ramautarsing RA, Park IU, Tso FK, Godbole S, D'Hauwers KWM, Sehnal B, Menezes LJ, Heráclio SA, Clifford GM. Cervical Determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. *Lancet Infectious Disease*. 2019 Aug; 19(8):880-891. Doi:10.1016/S1473-3099(19)30164-1. PMID: 31204304. PMCID: PMC6656696.
158. **Moscicki AB**, Yao TJ, Russell JS, Farhat S, Scott M, Magpantay L, Halec G, Shiboski CH, Ryder MI. Biomarkers of oral inflammation in perinatally HIV-Infected and perinatally HIV-exposed, uninfected youth. *Pediatric HIV/AIDS cohort study*. *J Clin Periodontol*. 2019 Nov;46(11):1072-1082. Doi: 10.1111/jcpe.13179. PMID: 31385616.. PMCID: PMC6800591.
159. Garber AK, Cheng J, Accurso EC, Adams SH, Buckelew SM, Kapphahn CJ, Kreiter A, Le Grange D, Machen VI, **Moscicki AB**, Saffran K, Sy AF, Wilson L, Golden NH. Weight loss and illness severity in adolescents with atypical anorexia nervosa. *Pediatrics*. 2019 Nov 6. Pii:e20192339. Doi: 10.1542/peds.2019-2339. PMID: 31694978.

160. Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, **Moscicki AB**, Mahmud SM, Wheeler CM, Rivera-Paredes B, Hernández-López R, León-Maldonado L, Salmerón J, Group. Frida Study Group. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus–based screening in Mexico. *JAMA Network Open*. 2019;Oct 2. 2(11):e1915781-e. doi: 10.1001/jamanetworkopen.2019.15781.
161. Mitra A, MacIntyre DA, Ntritsos G, Smith A, Tsilidis KK, Marchesi JR, Bennett PR, **Moscicki AB**, Kyrgiou M. The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. *Nat Commun*. 2020 Apr 24;11(1):1999. doi: 10.1038/s41467-020-15856-y. PMID: 32332850; PMCID: PMC7181700.
162. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, **Moscicki AB**, Nayar R, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. *J Low Genit Tract Dis*. 2020 Apr;24(2):102-131. doi: 10.1097/LGT.0000000000000525. PMID: 32243307; PMCID: PMC7147428.
163. Patel K, Karalius B, Powis K, Kacanek D, Berman C, **Moscicki AB**, Paul M, Tassiopoulos K, Seage GR 3rd. Trends in post-partum viral load among women living with perinatal HIV infection in the USA: a prospective cohort study. *Lancet HIV*. 2020;7(3):e184-e92. Epub 2019/12/25. doi: 10.1016/s2352-3018(19)30339-x. PubMed PMID: 31870676; PubMed Central PMCID: PMC6956402.
164. Ryder MI, Shiboski C, Yao TJ, **Moscicki AB**. Current trends and new developments in HIV research and periodontal diseases. *Periodontology 2000*. 2020;82(1):65-77. Epub 2019/12/19. doi: 10.1111/prd.12321. PubMed PMID: 31850628.
165. Garland SM, Stanley MA, Giuliano AR, **Moscicki AB**, Kaufmann A, Bhatla N, Woo YL. IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity". *Papillomavirus Res*. 2020;9:100195. Epub 2020/03/25. doi: 10.1016/j.pvr.2020.100195. PubMed PMID: 32205196; PubMed Central PMCID: PMC7109621
166. Brotherton J, Davies C. IPVS policy statement. Equity in cervical cancer prevention: for all and not just for some. *Papillomavirus Res*. 2020;9:100192.
167. Schulte F, King OD, Paster BJ, **Moscicki AB**, Yao TJ, Van Dyke RB, Shiboski C, Ryder M, Seage G, Hardt M; Pediatric HIV/AIDS Cohort Study. Salivary metabolite levels in perinatally HIV-infected youth with periodontal disease. *Metabolomics*. 2020 Sep 11;16(9):98. doi: 10.1007/s11306-020-01719-6. PMID: 32915320; PMCID: PMC7784422.
168. Garber AK, Cheng J, Accurso EC, Adams SH, Buckelew SM, Kapphahn CJ, Kreiter A, Le Grange D, Machen VI, **Moscicki AB**, Sy A, Wilson L, Golden NH. Short-term outcomes

of the study of refeeding to optimize inpatient gains for patients with anorexia nervosa: a multicenter randomized clinical trial. *JAMA Pediatr.* 2021 Jan 1;175(1):19-27. doi: 10.1001/jamapediatrics.2020.3359. PMID: 33074282; PMCID: PMC7573797.

169. Nichols, S.L., Brummel, S., Malee, K.M. Mellins CA, **Moscicki AB**, Smith R., Cuadra AM, Bryant K, Boyce CA, Tassiopoulos KK. . The role of behavioral and neurocognitive functioning in substance use among youth with perinatally acquired HIV infection and perinatal hiv exposure without infection. *AIDS Behav* (2021). PMID: 33616833.
170. **Moscicki AB**, Shi B, Huang H, Barnard E, Li H. Cervical-vaginal microbiome and associated cytokine profiles in a prospective study of HPV 16 acquisition, persistence, and clearance. *Front Cell Infect Microbiol.* 2020 Sep 25;10:569022. doi: 10.3389/fcimb.2020.569022. PMID: 33102255; PMCID: PMC7546785.
171. Perkins RB, Guido RL, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, **Moscicki AB**, Nayar R, Saraiya M, Sawaya G, Wentzensen N, Schiffman M. Response to letter to the editor regarding: 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. *J Low Genit Tract Dis.* 2020 Oct;24(4):426. doi: 10.1097/LGT.0000000000000562. PMID: 32732648.
172. **Moscicki AB**, Chang C, Vangala S, Zhou X, Elashoff DA, Dehlendorf C, Sawaya GF, Kuppermann M, Duron Y, Wyand FL, Navarro SK, Thiel de Bocanegra H. Effect of 2 interventions on cervical cancer screening guideline adherence. *Am J Prev Med.* 2021 Feb 22:S0749-3797(21)00057-X. doi: 10.1016/j.amepre.2020.11.015. Epub ahead of print. PMID: 33632649.
173. Golden NH, Cheng J, Kapphahn CJ, Buckelew SM, Machen VI, Kreiter A, Accurso EC, Adams SH, Le Grange D, **Moscicki AB**, Sy AF, Wilson L, Garber AK. Higher-calorie refeeding in anorexia nervosa:- 1-year outcomes from a randomized controlled trials. *Pediatrics.* 2021 Mar 22;147(4):e2020037135. doi: 10.1542/peds.2020-037135.PMID: 33753542
174. Cantos K, Franke MF, Tassiopoulos K, Williams PL, **Moscicki AB**, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study. Inconsistent sexual behavior reporting among youth affected by perinatal HIV exposure in the United States *AIDS Behav.* 2021 Apr 24. doi: 10.1007/s10461-021-03268-y PMID: 33893876
175. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, **Moscicki AB**, Nayar R, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. *J Low Genit Tract Dis.* 2021 Oct 1;25(4):330-331. doi: 10.1097/LGT.0000000000000628. PMID: 34542089.
176. Mitra A, MacIntyre DA, Paraskevaïdi M, **Moscicki AB**, Mahajan V, Smith A, Lee YS, Lyons D, Paraskevaïdis E, Marchesi JR, Bennett PR, Kyrgiou M. The vaginal microbiota

and innate immunity after local excisional treatment for cervical intraepithelial neoplasia. Genome Med. 2021 Nov 4;13(1):176. doi: 10.1186/s13073-021-00977-w. PMID: 34736529; PMCID: PMC8567681.

177. Barnard-Mayers R, Kouser H, Cohen JA, Tassiopoulos K, Caniglia EC, **Moscicki AB**, Campos NG, Caunca MR, Iii GRS, Murray EJ. A case study and proposal for publishing directed acyclic graphs: The effectiveness of the quadrivalent human papillomavirus vaccine in perinatally HIV Infected girls. J Clin Epidemiol. 2022 Jan 5:S0895-4356(21)00434-0. doi: 10.1016/j.jclinepi.2021.12.028. Epub ahead of print. PMID: 34998951.

**B. RESEARCH PAPERS – PEER REVIEWED (IN PRESS)**

*None*

**C. RESEARCH PAPERS – PEER REVIEWED (SUBMITTED)**

*None*

**RESEARCH PAPERS (NON-PEER REVIEWED)**

**A. RESEARCH PAPERS – NON-PEER REVIEWED**

*None*

**B. RESEARCH PAPERS – NON-PEER REVIEWED (IN PRESS)**

*None*

**C. RESEARCH PAPERS – NON-PEER**

*None*

**CHAPTERS**

1. **Moscicki AB** and Wolf W (Editors): Guidelines for diagnosis, treatment and interviewing of sexually transmitted diseases. San Francisco Department of Public Health, Bureau of Communicable Diseases. 1986.
2. **Moscicki AB**. Human papillomavirus: An old STD revisited. Contemporary Pediatrics 1989;6:12-48.
3. **Moscicki AB**, Shafer MA, Millstein SG, Irwin CE, Jr., Schachter J: Use and limitations of endocervical gram stains and mucopurulent cervicitis as predictors for C. trachomatis

- in adolescent females. *American Journal of Obstetrics and Gynecology* 1987;157:65-71. (Reprinted abstract and discussion). In: Oski FA, Stockman JA, III, eds. *The Yearbook of Pediatrics*, 1989. Chicago: Year Book Medical Publishers Inc., 1989, pp. 2810-83.
4. Shafer MA, **Moscicki AB**: Sexually transmitted diseases in adolescents. In: Hendee WR and Wilford B (Eds.), *The Health of Adolescents*. New York: Josey-Bass Publishers, 1991, pp. 211-249.
  5. **Moscicki AB**. Human papillomavirus in teenage girls: detection and management. *Human Sexuality* 1990:22-27.
  6. Schlossberger NM: Clinical assessment of reproductive health in the adolescent, section 4.4.3, pp. 57-60; Shafer MA, **Moscicki AB**: Sexually transmitted diseases, section 4.6, pp. 71-81. In: Rudolph A (Ed.), *Rudolph's Pediatrics*, 19th Edition). Norwalk, Connecticut: Appleton and Lange, 1991.
  7. Ellen J, **Moscicki AB**, Shafer MA: Human papilloma virus and herpes simplex virus. *Advances in Pediatric Infectious Diseases* 1994;9:97-124.
  8. Ford C, **Moscicki AB**: Control of sexually transmitted diseases in adolescents: The clinician's role. *Advances in Pediatric Infectious Diseases* 1995;10:263-305.
  9. **Moscicki AB**: Genital HPV infections in children and adolescents. *Obstetrics and Gynecology Clinics of North America* 1996;23:675-697.
  10. Lappa S, **Moscicki AB**: Pediatrician and the sexually active adolescent III: An STD Primer. *Pediatric Clinics of North America* 1997;44(6):1405-45.
  11. **Moscicki AB**: Human Papillomavirus Infections in Adolescents. *Pediatric Clinics of North America* 1999;46(4):783-807.
  12. Jay N, **Moscicki AB**: Human Papillomavirus Infections in Women, pp. 324-335. In: Goldman MB, Hatch MC (Ed.), *Women and Health*. San Francisco, CA: Academy Press, 2000.
  13. Moscicki AB: Pap smears and abnormal cervical cytology, pp. 1001-10. In: Neinstein LS (Ed.), *Adolescent Health Care: A Practical Guide*. Philadelphia, PA: Lippincott Williams and Wilkins, 2002.
  14. **Moscicki AB**. Cervical Cytology Screening in Teens. *Current Women's Health Reports* 2003;3:1-5.
  15. **Moscicki AB**: Human Papillomavirus, Chapter 243. In: Behrman RE, Kliegman RM (Eds.), *Nelson Textbook of Pediatrics*, 17th Edition. Philadelphia, PA: Saunders, 2004.
  16. **Moscicki AB**. Human papilloma virus, papanicolaou smears, and the college female.

Pediatric Clinics of North America 2005;52(1):163-77, ix.

17. **Moscicki AB**, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. *Vaccine* 2006 24 (Suppl 3): S42-51.
18. **Moscicki AB**, Singer A. The Cervical Epithelium During Puberty and Adolescence. In Jordan J, Singer A, Shafi M, Jones III H (eds.) *The Cervix* 2nd Edition. Oxford UK: Blackwell Publishing, 2006.
19. **Moscicki AB**. Human Papillomavirus (HPV) and its natural history in adolescents: implications for Cervical Cytology and HPV Testing. In Giordano A, Bovicelli A, Kurman RJ (eds.) *Molecular Pathology of Gynecologic Cancer*. Totowa, New Jersey: Humana Press, 2007.
20. **Moscicki AB**. Pap smears and abnormal cervical cytology. In: Neinstein LS (Ed.), *Adolescent Health Care: A Practical Guide* (5th edition). Philadelphia, PA: Lippincott Williams and Wilkins, 2007.
21. **Moscicki AB**. Clinical question: ask the expert. *J Low Genit Tract Dis* 2008. 12: 56-57.
22. **Moscicki AB**. Management of adolescents who have abnormal cytology and histology. *Obstet Gynecol Clin North Am* 2008;35:633-43.
23. **Moscicki AB**. Ch. 22 Human Papillomavirus Infections in Adolescents. In: Apgar BS, Spitzer M, Brotzman G (eds.) *Colposcopy: Principles and Practice.*, 2nd edition. New York, NY: Elsevier, 2008.
24. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L, Van Dyke R. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. *MMWR Recomm Rep* 2009;58:1-166. (**Moscicki** author HPV chapter)
25. **Moscicki AB**. Chapter 263: Human Papillomaviruses. In: Kliegman RM, Stanton BF, Geme JS, Schor N, Behrman, RE (eds.). *Nelson Textbook of Pediatrics*, 19th Edition. New York, NY: Elsevier, 2009.
26. **Moscicki, AB**. HPV disease and vaccines in adolescents. *Adolesc Med State Art Rev* 2010; 21: 347–363.
27. Slivka M, **Moscicki AB**, Shafer MA. Reproductive Growth and Development in the Female Adolescent. In: Rudolph C, Rudolph A, Lister G, First L, Gershon A (eds.) *Rudolph's Pediatrics*, 22nd edition. New York: McGraw Hill, 2011.



28. Hwang LY, **Moscicki AB**, Shafer MA. Sexually Transmitted Infections. In: Rudolph C, Rudolph A, Lister G, First L, Gershon A (eds). *Rudolph's Pediatrics*, 22nd edition. New York: McGraw Hill, 2011.
29. Hwang LY, **Moscicki AB**. Human papillomavirus infection in women. In Goldman MB, Troisi R, Rexrode K ed: *Women and Health*, 2nd ed. Elsevier. 2012.
30. **Moscicki AB**. Chapter 258: Human Papillomaviruses. In: Kliegman RM, Stanton BF, St Geme J, Schor N, eds. *Nelson Textbook of Pediatrics*. 20 ed. Philadelphia, PA: Elsevier, Inc; 2013.
31. **Moscicki, AB**. Chapter 50: Pap Smears and Abnormal Cervical Cytology. In: Neinstein LS, Katzman DK, Callahan T, Gordon CM, Joffe A, Rickert V (eds.). *Neinstein's Adolescent and Young Adult Health: A Practical Guide*, 6th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2015.
32. Hwang LY, **Moscicki AB**. Chapter 211: Human Papillomaviruses. In: Long SS, Prober CG, Fischer M, eds. *Principles and Practice of Pediatric Infectious Diseases, Fifth Edition*. Philadelphia, PA Elsevier; 2015.
33. **Moscicki AB**, Hwang LY, and Tassiopoulos K for section on Human Papillomavirus [2016 Update] in Siberry GK, GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Gnanashanmugam D, Mofenson LM, Kapogiannis B, Nesheim S; and the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at: <https://aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/0>.
34. Sebastian MR, **Moscicki A**. Reproductive Growth and Development in the Female Adolescent. In: Kline MW. eds. *Rudolph's Pediatrics, 23e* New York, NY: McGraw-Hill; <http://accesspediatrics.mhmedical.com/content.aspx?bookid=2126&sectionid=166914599>. Accessed September 28, 2018.
35. Hwang LY, **Moscicki A**. Sexually Transmitted Infections. In: Kline MW. eds. *Rudolph's Pediatrics, 23e* New York, NY: McGraw-Hill; <http://accesspediatrics.mhmedical.com/content.aspx?bookid=2126&sectionid=178132928>. Accessed September 28, 2018.
36. **Moscicki, A-B** Human Papillomavirus in In Bonnie Halpern-Felsher (Ed), *Encyclopedia of Child and Adolescent Health*. Elsevier. 2021, e-pub ahead of publication.

## **REVIEWS**

1. Moscicki AB: Genital human papillomavirus infections in adolescents. *Adolescent Medicine: State of the Art Reviews* 1990;1:451-470. Review.
2. Moscicki AB: Human papillomavirus infections. *Advances in Pediatrics* 1992;39:257-281. Review.
3. Kapphahn CJ, Moscicki AB: Pelvic inflammatory disease in adolescents. *Seminars in Pediatric Infectious Disease* 1993;4:102-112. Review.
4. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. *Clinical and Diagnostic Laboratory Immunology* 2001;8(2):209-20. Review
5. Moscicki AB. Cervical cytology testing in teens. *Current Opinion in Obstetrics and Gynecology* 2005;17(5):471-5. Review.
6. Moscicki AB. Impact of HPV infection in adolescent populations. *Journal of Adolescent Health* 2005;37(6 Suppl):S3-9. Review.
7. Moscicki AB. HPV infections in adolescents. *Disease Markers* 2007;23(4):229-34. Review.
8. Moscicki AB. Conservative Management of Adolescents With Abnormal Cytology and Histology. *J Natl Compr Canc Netw* 2008. 6: 101-106. Review.
9. Widdice LE, Moscicki AB. Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents. *J Adolesc Health* 2008 Oct;43(4 Suppl):S41-51. Review.
10. Moscicki AB. HPV Vaccines: today and in the Future. *J Adolesc Health* 2008 Oct;43(4 Suppl):S26-40. Review.
11. Moscicki AB. Vaginal microbicides: where are we and where are we going? *J Infect Chemother* 2008 Oct;14(5):337-341. Review.
12. Moscicki AB, Palefsky JM. Human papillomavirus in men: an update. *J Low Genit Tract Dis.* Jul 2011;15(3):231-234. Review.
13. Moscicki AB. HPV-associated cancers: it's not all about the cervix. *Prev Med.* Oct 1 2011;53 Suppl 1:S3-4. Review.
14. Kim SC, Feldman S, Moscicki AB. Risk of human papillomavirus infections in women with rheumatic disease: cervical cancer screening and prevention. *Rheumatology.* Volume 57. 2018 Jul 1. Pages v26–v33, <https://doi.org/10.1093/rheumatology/kex52>. PMID: 30137592. Review.



## **SUMMARY OF MY RESEARCH PROGRAM**

My current research activities involve the area of sexually transmitted diseases, specifically human papillomavirus infections (HPV) and HIV infections in adolescents.

### **Natural History of Human Papillomavirus: immune response and the role of cervical/vaginal microbiomes**

My research continues its primary focus on the natural history of HPV and immune response. In 2005, I received a MERIT award to continue this work, which began in 1990 and was funded through 2017. This study reflects the longest running cohort study of HPV with over 25 years of follow-up on many of the women. We continue to define important contributions specifically around defining patterns of HPV expression (i.e., latency, persistence and clearance), the role of cell-mediated immune responses and local TLR expression and T-regulatory cell using FoxP3 expression. Much of our work has been translated to therapeutics focusing on TLR agonists and therapeutic vaccines focusing on E7 and E6 antigens. The mucosal immune response is complex within the cervix because of the microbiologic milieu. We now have over 200,000 stored oral, vulvar/vaginal/cervical, and anal specimens which are ideal for examining factors affecting HPV persistence at different mucosal sites. We recently published a study demonstrating the in vivo intense inflammatory response resulting in clearance of HPV 16 and that the inflammation was in part driven by *Gardnerella vaginalis*, often thought of as a pathogen. Shifts from a anti-microbial state to anti-viral state likely result in what appears to be a microbial dysbiosis associated with an inflammatory state. In this case, host and microbiome-induced inflammation likely work synergistically to clear HPV 16 infections. My lab continues to work on examining the role of the microbiome in HPV clearance in women living with perinatal HIV infection.

### **Natural History of CIN-2 in Adolescents and the role of the microbiome.**

The overall low sensitivity and specificity of cytology to identify women with what is considered a true precancerous lesions [high grade squamous intra-epithelial lesions-(HSIL)] has resulted in many clinical and scientific groups questioning today's current screening practices. In an NIH funded study performed in Northern California Kaiser Permanente, we demonstrated that over 50% of CIN 2 lesions will regress. This data supported the ASCCP guidelines that recommend observation of CIN 2 in young women rather than immediate treatment. In collaboration with colleagues at the Imperial College of London, we recently examined the role of the microbiome in CIN 2 persistence from our stored specimens. We demonstrated that microbial dysbiosis was associated with CIN 2 persistence 12 months later, whereas microbiome with *Lactobacillus*-dominant microbiome. Manipulation of the local microbiome may lead to therapeutic avenues for CIN 2 treatment.

### **HPV and Young adults living with perinatally HIV infection**

HPV -associated morbidities excessively burden persons living with HIV including cervical, anal and oropharyngeal cancers. Perinatal HIV infection may also be a risk for future morbidities since HPV may be transmitted along with HIV in this population. HIV infected children may then also be more likely to have persistence as seen in adults. We showed that non sexually active girls who were perinatally HIV infected were more likely to have oral and genital HPV infections, specifically those under 12 years of age than their healthy HIV uninfected counterparts. Although the HPV vaccine is extremely efficacious in healthy populations, its

efficacy in immunocompromised populations is in question. In a study from the IMPAACT Network, we showed that children living with HIV had lower titers for HPV 6, 11, 16 and 18 than the uninfected comparison group. More recently, we examined antibody titers and cytology results from the Pediatric HIV and AIDS cohort (PHACS). Similar to the IMPAACT study, we found antibody titers to the vaccine types lower in the youth living with PHIV compared to uninfected youth. This was true whether they received 1, 2 or 3 full doses. Most alarming was that the vaccine appeared to have no efficacy in PHIV girls even when vaccinated before sexual debut with high rates of abnormal cytology. We have recently received funding from the NIH for two projects: one examining HPV genotyping and microbiome and metabolome assays in women living with PHIV who have abnormal cytology and a second, examining the role of the microbiome and metabolome in women with HPV persistence vs clearance.

### **Oral Health and Perinatally HIV infected (PHIV) children**

I am also involved in an oral health project within the Perinatally HIV and AIDS cohort which is an observational study of children living with perinatally HIV infection in the US and PR. My colleagues at UCSF and I were awarded a \$3,000,000 grant from NIDCR to specifically examine oral health in this population. In our initial publication, we found that caries were more common in children living (CL) with PHIV than the HIV exposed but uninfected (HEU) group and that integrase inhibitors (II) were at highest risk suggesting that these children on II should be referred more often to dental care. Microbiome analysis showed that there were several “healthy” microbes found less frequently in the PHIV children possibly explaining the higher rate of caries. Last, we examined several inflammatory biomarkers associated with gingival disease and found that inflammatory cytokines, markers of bone destruction and collagenolytic markers were elevated among children living with PHIV children with gingival inflammation suggesting that these biomarkers of inflammation may identify increased risk for progressive disease. We were awarded another supplement from NIDCR to perform follow-up examinations on these same individuals to study predictors of periodontal disease progression.

### **Dissemination of cervical cancer screening guidelines for young women**

Although cervical cancer screening has saved thousands of women’s lives, data also show that overscreening results in overtreatments leading to huge unnecessary costs and negative consequences such as premature delivery. Over the past decade, national guidelines have changed substantially to avoid negative outcomes, such that routine screening is started later in life, completed earlier, and performed at greater intervals. These changes often result in confusion among women and providers. We recently completed a project funded by PCORI that examined the effectiveness of a patient-oriented educational intervention designed to increase adherence to the new US cervical cancer screening guidelines and guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. The results were promising and we were awarded a PCORI dissemination grant to increase the use of the intervention nationwide.

### **Translation of Research to Policy**

Much of our work, specifically in HPV, has been translated to National Guidelines. My work in the natural history of HPV in general populations of adolescents and young women as well as

HIV infected influenced much of the new guidelines for cervical cancer screening and triage of abnormal cytology in young women with and without HIV. Our observations led to the new guidelines moving initial age of screening from shortly after the onset of sexual activity to screening at the age of 21 years and now 25 years and supported the recommendations to observe young women with low grade squamous intra-epithelial lesions (SIL) and HSIL in up to two years before further intervention. Our work was also extrapolated to influence guidelines for HIV infected adolescents and for anal cancer screening in at risk groups of women.